Compositions and methods for treating cancer and autoimmune diseases
Small molecule compounds targeting the GITR-GITRL receptor complex enhance T effector cell responses, addressing immunosuppression in cancer and autoimmune diseases, improving treatment efficacy and safety.
Patent Information
- Application Number
- JP2024120839
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-08-08
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments face challenges due to cancer-associated immunosuppression mediated by T regulatory (Treg) cells, which hinder effective immune responses against tumors, and autoimmune diseases are poorly managed by existing therapies that can cause immune-related adverse events.
Development of small molecule compounds that modulate the glucocorticoid-induced TNFR family-related receptor (GITR) to stabilize the GITR-GITRL receptor complex, disrupting Treg-mediated tolerance and enhancing T effector cell responses in cancer and autoimmune diseases.
The compounds effectively disrupt immunosuppression in cancer and autoimmune diseases, allowing for targeted tumor-specific drug delivery and reducing toxicity, while improving treatment efficacy and minimizing adverse events.
Smart Images

Figure 2024156758000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates generally to compositions and methods for treating cancer and inflammatory diseases (eg, autoimmune diseases). [Background technology]
[0002] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The following description contains information that may be useful in understanding the present invention. No admission is made that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0003] Regulatory T cells (Treg cells) express high levels of glucocorticoid-induced tumor necrosis factor-related receptor (GITR), whereas resting T cells express low levels that increase upon activation. Regulation of GITR / GITR-ligand (GITRL) interactions results in enhanced immune responses. There is a need in the art for agents that regulate GITR / GITRL to treat cancer or autoimmune diseases.
[0004] GITR / GITRL is a member of the tumor necrosis factor receptor superfamily (TNFRSF), TNFRSF18, which is also called activation-induced TNFRSF (AITR).
[0005] Cancer immunotherapy is a new tool in the fight against cancer progression. Although immune suppression at tumor sites is contributed by various stromal cells such as macrophages and cancer-associated fibroblasts, checkpoint-mediated T cell suppression has been identified as a potential therapeutic target. Checkpoint molecules are PD-1, OX40, CTLA-4 and GITR. Currently, antibody-based therapeutics targeting these checkpoint molecules are used in the clinic, except for molecules targeting GITR, which is the main regulator of Foxp3+ T regulatory (Treg) cells.
[0006] The innovative aspects of this technology came from the identification of the GITR receptor complex as a therapeutic target for immunotherapy and the identification of small molecules to overcome cancer-associated immune suppression. We identified small molecule compounds that can break T-reg-mediated tolerance by stabilizing the GITR-GITRL receptor. The development of small molecule therapeutics was based on the crystal structure determined by Dr. Murali. While small molecules targeting the PD-1 / PD-L1 pathway have been reported by pharmaceutical companies, they have not progressed to clinical use due to lack of specificity. We identified small molecules specific for GITRL by biophysical assays. Thus, the present invention provides a novel means to disrupt immune suppression in cancer or reduce T-eff cells in autoimmune diseases. Being a small molecule offers the advantage of delivering the drug in a tumor-specific manner, thereby reducing the toxicity associated with current checkpoint inhibitors.
[0007] Cancer-associated immune suppressive elements are responsible for poor clinical responses to current cancer therapies. In particular, immune suppressive T cells play a dominant role in poor clinical responses. Agents targeting these T cell populations, commonly referred to as “checkpoint inhibitors”, have revolutionized cancer immunotherapy. In this category, antibodies against PD-1 and CTLA-4 have shown success. However, response rates (RR) to PD-1 or PD-L1 antibodies as single agents remain around 15–30%, and many patients who receive anti-PD-1 or anti-PD-L1 therapy are at risk of developing immune-related adverse events (IRAEs), such as Crohn’s disease, lupus erythematosus, and rheumatoid arthritis (Rosenberg et al., 2016).
[0008] Glucocorticoid-induced TNR family related protein Ligand (GITRL) is a T cell cytokine that costimulates T effector (T-eff) cells via the GITR receptor and neutralizes the suppressive activity of T regulatory (Treg) cells, and is thought to inhibit Foxp3 expression.
[0009] Due to its central role in regulating Tregs, the GITR receptor complex is considered an optimal therapeutic target for treating autoimmunity and cancer. Indeed, the anti-GITR antibody MK-4166 has recently been shown to eradicate established melanoma and colon tumors in preclinical mouse models (Mahne et al., 2017).
[0010] As a costimulatory cytokine, the GITR receptor and its ligands belong to the TNF / TNFR superfamily and have been extensively studied. GITR is constitutively expressed at high levels on CD4+CD25+ regulatory T cells and activated T cells. GITR ligand (GITRL) is constitutively expressed on antigen-presenting cells. Signaling through GITR enhances Treg suppression or decreases Treg suppression and enhances T effector cells or the ability of T effector cells to recognize and respond to self-antigens, e.g., cancer / tumor cells. Pharmacological manipulation of GITR signaling may have applications in antitumor therapy and autoimmunity. Summary of the Invention
[0011] The following embodiments and aspects thereof are described and illustrated in connection with systems, compositions, and methods, which are meant to be exemplary and illustrative, and not limiting in scope.
[0012] Provided in the present invention is a compound selected from: Naming RMGL171102 [ka] and Naming RMGL171104 [ka] . Also provided by the present invention is a compound of formula (I): [ka] , or a pharma- ceutically acceptable salt, ester or prodrug thereof; where: R1 is hydrogen or an optionally substituted substituent; R2 is hydrogen or an optionally substituted substituent; R3 is hydrogen or an optionally substituted substituent; R4 is hydrogen or an optionally substituted substituent; R5 is hydrogen or an optionally substituted substituent; R6 is hydrogen or an optionally substituted substituent; R7 is hydrogen or an optionally substituted substituent; and R8 is hydrogen or an optionally substituted substituent; wherein, optionally, two or more of R1, R2, R3, R4, R5, R6, R7, or R8 may be joined together to form one or more rings.
[0013] Further provided in the present invention is a compound of formula (II): [ka] , or a pharma- ceutically acceptable salt, ester or prodrug thereof; where: R9 is hydrogen or an optionally substituted substituent; R10 is hydrogen or an optionally substituted substituent; R11 is hydrogen or an optionally substituted substituent; R12 is hydrogen or an optionally substituted substituent; R13 is hydrogen or an optionally substituted substituent; R14 is hydrogen or an optionally substituted substituent; R15 is hydrogen or an optionally substituted substituent. R16 is hydrogen or an optionally substituted substituent; wherein, optionally, two or more of R9, R10, R11, R12, R13, R14, R15, or R16 may be joined together to form one or more rings.
[0014] Provided by the present invention are GITR antagonists selected from any one or more of the compounds having the structure set forth in Formula II.
[0015] Further provided is a composition comprising the GITR antagonist described herein.Also provided is a method of using the GITR antagonist to treat inflammatory disease, particularly autoimmune disease, in a subject by administering to the subject a therapeutically effective amount of a composition comprising the GITR antagonist.In some embodiments, the method further comprises administering to the subject an existing treatment for autoimmune disease.In various embodiments, the composition comprising the GITR antagonist and the existing treatment are administered simultaneously or sequentially.
[0016] Also provided by the present invention are GITR agonists selected from any one or more of the compounds having the structure set forth in Formula I.
[0017] Also provided by the present invention is a GITR agonist selected from any one or more or all of SEQ ID NO:1 and / or SEQ ID NO:2, or a variant, derivative or functional equivalent thereof.
[0018] The present invention further provides a composition comprising the GITR agonist described herein.Also provided is a method of using the GITR agonist to treat cancer in a subject by administering a therapeutically effective amount of a composition comprising the GITR agonist.In some embodiments, the method further comprises administering an existing cancer treatment to the subject.In various embodiments, the composition comprising the GITR agonist and the existing treatment are administered sequentially or simultaneously.
[0019] In one aspect, the invention relates to a method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a GITR / GITRL agonist as described herein.
[0020] The GITR / GITRL agonist can be administered to a subject simultaneously or sequentially with an existing therapy for cancer. The cancer can be T cell / B cell lymphoma (Hodgkin's lymphoma and / or non-Hodgkin's lymphoma), brain cancer, breast cancer, colon cancer, lung cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, kidney cancer, skin cancer, melanoma, head and neck cancer, brain cancer, and skin cancer such as prostate cancer, androgen-dependent prostate cancer or androgen-independent prostate cancer.
[0021] In another aspect, the invention is directed to treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a sample of enriched or expanded T-eff cells, where the T-eff cells are enriched or expanded by contacting the T-eff cells with a GITR / GITRL agonist as described herein with or without the presence of T-reg cells. The T-eff cells or T-reg cells can be autologous or allogeneic to the subject.
[0022] In another aspect, the present invention relates to a method for enriching or expanding T-eff cells, comprising contacting T-eff cells with a GITR / GITRL agonist as described herein, in the presence or absence of T-reg cells, preferably in the presence of T-reg cells. T-eff and T-reg cells may be present in a starting ratio of about 1:1.
[0023] In another aspect, the present invention relates to a method for treating an inflammatory disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a GITR / GITRL antagonist as described herein. The inflammatory disease is an autoimmune disease.
[0024] The GITR / GITRL antagonist can be administered to a subject simultaneously or sequentially with existing treatments for inflammatory diseases.The autoimmune disease can be rheumatoid arthritis, osteoarthritis, asthma, dermatitis, psoriasis, cystic fibrosis, late transplant and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, Hashimoto's thyroiditis, polymyositis, scleroderma, Addison's disease, vitiligo, pernicious anemia, glomerulonephritis and pulmonary fibrosis, inflammatory bowel disease, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, postangioplasty restenosis, chronic obstructive pulmonary disease (COPD), Graves' disease, gastrointestinal allergy, conjunctivitis, atherosclerosis, coronary artery disease, angina, cancer metastasis, small artery disease, graft-versus-host disease, or mitochondrial-related syndrome.Preferably, the autoimmune disease can be inflammatory bowel disease.
[0025] In another aspect, the invention provides a method for treating an inflammatory disease in a subject in need thereof, comprising administering a therapeutically effective amount of a GITR / GITRL antagonist to engineered T cells that have been enriched or expanded in vivo or ex vivo for T-regs, wherein the engineered T cells enrich or expand T-reg cells and modify T-eff cells by contacting the T-eff cells with a GITR / GITRL antagonist in the presence or absence of T-reg cells. The T-eff or T-reg cells can be autologous or allogeneic to the subject.
[0026] In another aspect, the invention relates to a method of enriching or expanding T-reg cells, comprising contacting T cells with a GITR / GITRL antagonist, with or without the presence of T-eff cells. Preferably, T-reg cells are initially present, and the T-eff and T-reg cells may be present at a starting ratio of about 1:1. [Brief description of the drawings]
[0027] Exemplary embodiments are illustrated in the referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative and not restrictive.
[0028] [Figure 1] Figure 1A-1B shows the results where PBMCs were isolated (Ficoll, GE Healthcare) from WBC cones taken from healthy platelet donors. Cells were washed and passed through a 40 μm cell strainer before staining with T cell surface antibodies. Cells were then placed on a cell sorter (BD FACSARIA III). Specific cell populations were collected: CD4+CD25- cells (T effector cells), CD4+CD25+CD45RA+CD127- cells (T regulatory cells), and CD3- cells (acting as Antigen Presenting Cells, APCs). T effector cells were labeled with CellTrace CFSE (Invitrogen) and washed extensively before cell counting. Effector cells and T-regs were then mixed together at a 1:1 ratio in culture medium (RPMI 1640, 10% FBS, Pen-Strep and 1% NEAA) enhanced with anti-CD3 (3 μg / ml) and anti-CD28 (2 μg / ml) antibodies. APCs were treated with mitomycin (50 μg / ml) for 30 min at 37°C in a 5% CO2 incubator and then added to the culture mix (APC:T-eff 2:1) as a proliferation co-stimulator. The cell mixture was incubated at 37°C in a 5% CO2 incubator for 6 days, after which it was re-stained with T cell surface markers (CD4, CD25) and sent for FACS analysis. (A) T-eff fully stimulated; (B) T-eff fully stimulated + T-reg (1:1).
[0029] [Figure 2-1] 2A-2C show FACS analysis for (A) T-eff full stimulation + 11702 (5 μl); (B) T-eff full stimulation + 11702 (25 μl); (C) T-eff full stimulation + 11702 (50 μl).
[0030] [Figure 2-2]Figures 2D-2F show FACS analysis for (A) T-eff full stimulation + 11702 (5 μl) + T-reg; (B) T-eff full stimulation + 11702 (25 μl) + T-reg; (C) T-eff full stimulation + 11702 (50 μl) + T-reg.
[0031] [Figure 3-1] Figures 3A-3C show FACS analysis for (A) T-eff full stimulation + 11704 (5 μl); (B) T-eff full stimulation + 11704 (25 μl); (C) T-eff full stimulation + 11704 (50 μl).
[0032] [Figure 3-2] Figures 3D-3F show FACS analysis for (A) T-eff full stimulation + 11704 (5 μl) + T-reg; (B) T-eff full stimulation + 11704 (25 μl) + T-reg; (C) T-eff full stimulation + 11704 (50 μl) + T-reg.
[0033] [Figure 4] Figure 4 shows a summary table of the effects of agonist and antagonist compounds and their effects on T cell effector proliferation changes. PBMCs were isolated and specific human T cell populations were collected as follows: CD4+CD25- cells (T effector cells), CD4+CD25+CD45RA+CD127- cells (T regulatory cells) and CD3- cells (acting as antigen presenting cells, APCs). T effector cells were then labeled with CellTrace CFSE and effector cells and T-regs were mixed together at a 1:1 ratio in culture medium (RPMI 1640, 10% FBS, Pen-Strep and 1% NEAA) enhanced with anti-CD3 (3 μg / ml) anti-CD28 (2 μg / ml) antibodies. APCs were treated with mitomycin (50 μg / ml) for 30 min at 37°C in a 5% CO2 incubator, then added to the culture mix (APC:T-eff 2:1) as a proliferation co-stimulator, incubated and sent for FACS analysis. Molecules 11702 agonist and 11704 antagonist were added to the treatment groups at a concentration gradient of 5 μM, 25 μM and 50 μM, respectively.
[0034] [Diagram 5] FIG. 5 shows a summary graphical representation of the table in FIG.
[0035] [Figure 6A] Figures 6A-6C show that GITR agonist 11702 inhibits melanoma growth through T-eff proliferation and T-reg inhibition in tumors. After implantation of B16 melanoma, C57 BL mice were treated with 11702 GITR agonist or DMSO control. (A) After intraperitoneal administration of 30 mg / kg GITR agonist, animals survived longer (p=0.0333, log-rank). [Figure 6B] (B) Tumor volume was inhibited in 11702 treated animals (p<0.05, analysis of variance: Anova). [Figure 6C] (C) FAC analysis of tumor-infiltrating lymphocytes demonstrated an increased presence of activated CD4+ cells and an increase in effector memory cytotoxic CD8+ T cells. Both populations showed increased PD-1 expression, suggesting that IFNγ induces upregulation of PD-1, leading to a potential synergistic effect of this agent with PD-1 checkpoint blockade. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0036] All references cited herein are incorporated by reference in their entirety as if fully set forth. Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Definitions of common terms in molecular biology are provided below to allow one of skill in the art general reference to many of the terms used in this application; Benjamin Lewin, Gens V, published by Oxford University Press, 1994(ISBN 0-19-854287-9); The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994(ISBN 0-632-02182-9); and Robert A. Meyers(ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, Allen et al., Remington: The Science and Practice of Pharmaceutical Press(2012.9.15); Hornyak et al., Introduction to Nanoscience and Nanotechnology, CRC Press(2008); Singleton and Sainsbury, Dictionary of Microbiology and Molecular Biology 3rd ed., J. Wiley & Sons(New York, NY 2006); Smith, March's Advanced Organic Chemistry Reactions, Mechanism and Structure 7 th ed., J. Wiley & Sons(New York, NY 2013); Singleton, Dictionary of DNA and Genome Technology 3 rd ed., Wiley-Blackwell(November 28, 2012); and Green and Sambrook, Molecular Cloning: A Laboratory Manual 4th ed., Cold Spring Harbor Laboratory Press(Cold Spring Harbor, NY 2012). For references regarding antibody preparation methods see; Greenfield, Antibodies A Laboratory Manual 2 nd ed., Cold Spring Harbor Press (Cold Spring Harbor NY, 2013); Kohler and Milstein, Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion, Eur. J. Immunol 1976.7.6(7):511-9; Queen and Selick, Humanized immunoglobulins, U.S. Pat. No. 5,585,089 (December 1996); and Riechmann et al., Reshaping human antibodies for therapy, Nature 1988. March 24,332(6162):323-7.
[0037] Those skilled in the art will recognize many methods and materials that are similar or equivalent to those described herein. Other features and advantages of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate, by way of example, various features of embodiments of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For convenience, certain terms used herein in the specification, examples, and appended claims are collected here.
[0038] Unless otherwise stated or implied from the context, the following terms and phrases include the meanings provided below. Unless otherwise stated explicitly or clearly from the context, the following terms and phrases do not exclude the meaning that the term or phrase has acquired in the relevant art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. It should be understood that the invention is not limited to the specific methodology, protocols, and reagents, etc. described herein, which may vary. The definitions and terms used herein are provided to help describe certain embodiments and are not intended to limit the invention described in the claims, since the scope of the invention is limited only by the claims.
[0039] As used herein, "RMGL171102," "RMGL171103," and "RMGL171104" are referred to interchangeably as compounds 11702, 11703, and 11704, respectively.
[0040] As used herein, "cell therapy" is also considered an ex vivo therapy, in which cells are grown or treated outside the body and then returned to the patient by injection or transplantation. The treated cells can be autologous or allogeneic to the patient.
[0041] As used herein, the term "comprising" or "comprisings" is used in reference to compositions, methods, and their respective components, which may or may not be useful, but are useful to those of skill in the art for the inclusion of unspecified elements. General terms used herein are generally intended as "open" terms. For example, those of skill in the art will understand that the term "including" should be interpreted as "including but not limited" and the term "having" should be interpreted as "having at least". However, the open term "comprising" as a synonym for terms such as including, containing, or having, used herein to describe and claim the present invention, may alternatively be described using alternative terms such as "consisting of" or "consisting essentially of".
[0042] Unless otherwise indicated, the terms "a" and "an" and "the" and similar references used in the context of describing particular embodiments of this application (particularly in the context of the claims) may be construed to include both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand way of individually referring to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated herein as if it were individually recited herein. All methods described herein may be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided with respect to particular embodiments herein is intended merely to make the application more clear and does not limit the scope of the application as otherwise claimed. The abbreviation "for example" is derived from the Latin word exemplary satisfaction and is used herein to indicate a non-limiting example. Thus, the abbreviation "for example" is synonymous with the term "for example." No anguage in the specification should be construed as indicating any non-claimed element essential to the practice of the application.
[0043] "Optional" or "optionally" means that the situation described below may or may not occur, and thus this specification includes cases where the situation occurs and cases where it does not occur.
[0044] As used herein, the term "agent" or "agents" refers to any one or more of the proteins, peptides, peptidomimetics, compounds, chemical compounds, small molecules, organic compounds, inorganic compounds, antisense compounds, antibodies, protease inhibitors, hormones, chemokines, cytokines, or compounds of interest of the invention as described herein. In one embodiment, the agent is a GITR agonist (e.g., a peptide having the sequence shown in SEQ ID NO:1 or SEQ ID NO:2, or an agent having the structure of Formula I, particularly the compound designated RMGL171102 (also known as compound 11702). In a further embodiment, the agent is a GITR antagonist (e.g., an agent having the structure of Formula II). In a further embodiment, the agent is a GITR antagonist designated RMGL171104 (also known as compound 11704).
[0045] As used herein, the terms "treat", "treatment", "treating" and "amelioration" refer to both therapeutic and prophylactic treatments, the purpose of which is to prevent, reverse, alleviate, alleviate, suppress, alleviate, slow or stop the progression or severity of a symptom or condition. "Treat" includes reducing or alleviating at least one adverse effect or symptom of a condition or condition. Treatment is generally "effective" if one or more symptoms or clinical markers are reduced. Alternatively, it is "effective" if the progression of a disease, disorder or medical condition is reduced or stopped. That is, "treatment" includes not only the improvement of symptoms or markers, but also the halting or at least slowing of the progression or worsening of symptoms that would be expected in the absence of treatment. Also, "treatment" refers to a condition that seeks or obtains a beneficial result or reduces the chances of an individual's development, even if ultimately unsuccessful. Those in need of treatment include those already with the condition, as well as those prone to having the condition or those in whom the condition is to be prevented.
[0046] As used herein, a therapeutic agent that "prevents" a disorder or condition refers to a compound that, in a statistical sample, reduces the occurrence of the disorder or condition in a treated sample compared to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition compared to an untreated control sample.
[0047] The terms "decrease," "reduced," "reduction," or "inhibit" are all used herein to mean a decrease or reduction in a characteristic, level, or other parameter by a statistically significant amount. In some embodiments, "reduce," "reduction," "decrease," or "inhibit" typically means a decrease of at least 10% compared to a baseline level (e.g., in the absence of a given treatment), and includes, for example, a decrease of at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 98%, at least about 99%, or more. As used herein, "reduction" or "inhibition" does not encompass complete inhibition or reduction when compared to a reference level. "Complete inhibition" is 100% inhibition when compared to a reference level. The reduction can preferably be down to a level that is accepted as within the normal range for individuals without a given disorder.
[0048] The terms "inclesed", "increase" or "enhance" or "activate" are all used herein to generally mean an increase in a property, level, or other parameter by a statically significant amount, and for the avoidance of any doubt, the terms "inclesed", "increase" or "enhance" or "activate" mean an increase of at least 10% compared to a reference level, for example, at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or up to at least about 90%, or an increase of 100% or any increase between 10-100% compared to a reference level, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold, at least about 10-fold increase, at least about 20-fold increase, at least about 50-fold increase, at least about 100-fold increase, at least about 1000-fold increase or more.
[0049] As used herein, "cancer" or "tumor" refers to the uncontrolled proliferation of cells that interferes with the normal function of bodily organs and systems. A subject with cancer or tumor is one that has objectively measurable cancer cells present in the subject's body. Included in this definition are benign and malignant cancers, as well as dormant tumors or micrometastases. Cancer that migrates from its original location and origin of vital organs can ultimately lead to the death of the subject through the deterioration of the affected organ's function. Examples of cancer include B-cell lymphoma (Hodgkin's lymphoma and / or non-Hodgkin's lymphoma), brain cancer, breast cancer, colon cancer, lung cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, kidney cancer, melanoma, head and neck cancer, brain cancer, and prostate cancer, further including, but not limited to, androgen-dependent prostate cancer and androgen-independent prostate cancer.
[0050] The term "effective amount" or "therapeutically effective amount" as used herein refers to an amount of one or more GITR agonists or GITR antagonists, or an amount of a pharmaceutical composition comprising one or more GITR agonists or GITR antagonists disclosed herein, to reduce at least one or more symptoms of a disease or disorder, and relates to an amount of a pharmacological composition sufficient to provide a desired effect. As used herein, the phrase "therapeutically effective amount" refers to an amount of a composition sufficient to treat a disorder, at a reasonable benefit / risk ratio applicable to any medical treatment.
[0051] As used herein, "peptidomimetics" are small protein-like chains designed to mimic protein function. They may be modifications of existing peptides or may be de novo designed to mimic known peptides. They may be, for example, peptoids and / or β-peptides and / or D-peptides.
[0052] "Recombinant virus" refers to a virus that has been genetically altered (eg, by the addition or insertion) of a heterologous nucleic acid construct into the particle.
[0053] A "gene" or "coding sequence" or a sequence "encoding" a particular protein or peptide is a nucleic acid molecule that is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide, either in vitro or in vivo, when placed under the control of appropriate regulatory sequences. The boundaries of the gene are determined by a start codon at the 5' (i.e., amino) terminus and a translation stop codon at the 3' (i.e., carboxy) terminus. Genes can include, but are not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and even synthetic DNA sequences. A transcription termination sequence is usually located 3' to the gene sequence.
[0054] The term "control element" collectively refers to promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which provide for the replication, transcription, and translation of a coding sequence in a recipient cell. Not all of these control elements need always be present so long as the selected coding sequence is capable of being replicated, transcribed, and translated in an appropriate host cell.
[0055] The term "promoter region" is used herein in its conventional sense to refer to a nucleotide region that contains a DNA regulatory sequence derived from a gene capable of binding RNA polymerase and initiating transcription of a downstream (3'-direction) coding sequence.
[0056] "Operably linked" refers to an arrangement of elements that are configured so that such components perform their normal function, such that control elements operably linked to a coding sequence are capable of affecting the expression of the coding sequence. Control elements need not be contiguous with the coding sequence, so long as they function to direct its expression. Thus, for example, intervening untranslated but transcribed sequences can be present between the promoter sequence and the coding sequence, and the promoter sequence can still be considered "operably linked" to the coding sequence.
[0057] "Gene transfer" or "gene delivery" refers to a method or system for reliably inserting foreign DNA into a host cell. Such methods may result in transient expression of unintegrated transferred DNA, extrachromosomal replication and expression of the transferred replicon (e.g., episome), or integration of the transferred genetic material into the genomic DNA of the host cell. Gene transfer offers a unique approach for the treatment of acquired and inherited diseases. Many systems for gene transfer into mammalian cells have been developed. See, for example, U.S. Pat. No. 5,399,346. Examples of known vehicles for gene transfer include adenoviruses and recombinant adenoviruses (RAd), adeno-associated viruses (AAV), herpes simplex virus type 1 (HSV-1), and lentiviruses (LV).
[0058] "Genetically modified cell", "genetically engineered cell" or "modified cell" as used herein refers to a cell that expresses a polynucleotide encoding a polypeptide having any one or more of the sequences of SEQ ID NO:1 or SEQ ID NO:2, or a variant, derivative, pharmaceutical equivalent, peptidomimetic, or analog thereof.
[0059] "Naked DNA" as used herein refers to DNA encoding a polypeptide having any one or more of the sequences of SEQ ID NO:1 or SEQ ID NO:2, or a variant, derivative, pharmaceutical equivalent, peptidomimetic, or analog thereof, cloned into a suitable expression vector in proper orientation for expression. Viral vectors that may be used include, but are not limited to, SIN lentiviral vectors, retroviral vectors, foamy viral vectors, adeno-associated viral (AAV) vectors, hybrid vectors and / or plasmid transposons (e.g., the sleeping beauty transposon system) or integrase-based vector systems. Other vectors that may be used in connection with alternative embodiments of the invention will be apparent to those of skill in the art.
[0060] As used herein, "polynucleotide" includes, but is not limited to, DNA, RNA, cDNA (complementary DNA), mRNA (messenger RNA), rRNA (ribosomal RNA), shRNA (small hairpin RNA), snRNA (nucleolar RNA), snoRNA (short nucleolar RNA), miRNA (microRNA), genomic DNA, synthetic DNA, synthetic RNA, and / or tRNA.
[0061] The term "transfection" is used herein to refer to the uptake of foreign DNA by a cell. A cell has been "transfected" when exogenous DNA has been introduced into the cell membrane. Many transfection techniques are generally known in the art. See, for example, Graham et al., Virology, 52:456 (1973); Sambrook et al., Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York (1989); Davis et al., Basic Methods in Molecular Biology, Elsevier (1986) and Chu et al., Gene 13:197 (1981). Such techniques can be used to introduce one or more exogenous DNA moieties (e.g., plasmid vectors and other nucleic acid molecules) into a suitable host cell. The term refers to both stable and transient uptake of genetic material.
[0062] As used herein, "vector," "cloning vector," and "expression vector" refer to a vehicle by which a polynucleotide sequence (e.g., a foreign gene) can be introduced into a host cell in order to transform the host and promote expression (e.g., transcription and translation) of the introduced sequence. Vectors include plasmids, phages, viruses, and the like.
[0063] A "beneficial outcome" or "desired outcome" includes, but is not limited to, reducing or alleviating the severity of a disease state, preventing the disease state from worsening, preventing the onset of a disease state, reducing the chances that a patient will develop a disease state, reducing morbidity and mortality, and increasing the patient's life span or life expectancy. As non-limiting examples, a "beneficial outcome" or "desired outcome" can be the alleviation of one or more symptoms, reducing the extent of a defect, stabilizing (i.e., not worsening) the cancer, delaying or slowing the progression of the cancer, and ameliorating or alleviating symptoms associated with the cancer.
[0064] As used herein, "disease," "condition," and "disease state" may include, but is in no way limited to, any form of cancer or autoimmune disease.
[0065] As used herein, the term "administering" refers to the placement of an agent or composition as disclosed herein into a subject by a method or route that results in at least partial localization of the agent or composition at a desired site. "Route of administration" refers to any route of administration known in the art, including, but not limited to, oral, topical, aerosol, nasal, inhalation, intraanal, perianal, mucosal, transdermal, enteral, or topical. "Parenteral" generally refers to routes of administration related to injection, including intratumoral, intracranial, intraventricular, intrathecal, epidural, intradural, intraorbital, infusion, intraarticular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intravascular, intravenous, intraarterial, subarachnoid, subcutaneous, transmucosal, or transtracheal. Via parenteral routes, the agent or composition may be in the form of a solution or suspension for infusion or injection, or may be a lyophilized powder. Via the enteral route, the agent or composition may be in the form of a capsule, gel capsule, tablet, sugar-coated tablet, syrup, suspension, solution, powder, granule, emulsion, microsphere or nanosphere, or lipid or polymer vesicle that allows for controlled release. Via the topical route, the agent or composition may be in the form of an aerosol, lotion, cream, gel, ointment, suspension, solution, or emulsion. In one embodiment, the agent or composition may be provided in powder form and mixed with a liquid, such as water, to form a beverage. According to the present invention, "administering" may be self-administering, e.g., a subject consuming a composition disclosed herein is considered to be "administering."
[0066] As used herein, "subject" means a human or an animal. Typically, an animal is a vertebrate such as a primate, a rodent, a domestic animal, or a game animal. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, and macaques (e.g., Rhesus). Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Domestic and game animals include cattle, horses, pigs, deer, bison, buffalo, feline species, such as domestic cats, and canine species, such as dogs, foxes, and wolves. The terms "patient," "individual," and "subject" are used interchangeably herein. In one embodiment, the subject is a mammal. The mammal can be, but is not limited to, a human, a non-human primate, a mouse, a rat, a dog, a cat, a horse, or a cow. Additionally, the methods described herein can be used to treat domestic animals and / or pets. In one embodiment, the subject is a human.
[0067] As used herein, "mammal" refers to any member of the class Mammalia, including, but not limited to, humans and non-human primates (e.g., chimpanzees and other human and simian species); domestic animals (e.g., cows, sheep, pigs, goats, and horses); farm animals (e.g., dogs and cats); laboratory animals (e.g., rodents (e.g., mice, rats, and guinea pigs), etc.). The term does not denote a particular age. Thus, adult and neonatal subjects, as well as fetuses, are intended to be included within the scope of this term.
[0068] The subject may be one who has been previously diagnosed or identified as suffering from or having a condition (e.g., cancer or an autoimmune disease) that requires treatment or one or more complications associated with the condition, and optionally has already been treated for the condition or one or more complications associated with the condition. Alternatively, the subject may also be one who has not previously been diagnosed with the condition or one or more complications associated with the condition. For example, the subject may be one who exhibits one or more risk factors for a condition, or one or more complications associated with the condition, or one who does not exhibit risk factors. For example, the subject may be one who exhibits one or more symptoms for a condition, or one or more complications associated with the condition, or one who does not exhibit symptoms. A "subject in need" of diagnosis or treatment for a particular condition may be a subject suspected of having the condition, a subject diagnosed with the condition, a subject who has already been treated or is being treated for the condition, a subject who has not been treated for the condition, or a subject who is at risk of developing the condition.
[0069] "At risk" is intended to mean an increased risk compared to a normal subject or compared to a control group, e.g., a patient population. Thus, subjects with certain markers may be identified as having an increased risk for a particular disease or disorder and in need of further testing. "Increased risk" or "elevated risk" means any statistically significant increase in the probability, e.g., that a subject has a disorder. The risk is preferably increased by at least 10%, more preferably at least 20%, and even more preferably at least 50% relative to the control group to which the comparison is being made.
[0070] Immunosuppressants include any agent or compound that has the ability to reduce the body's immune system response. In some embodiments, the immunosuppressant is a corticosteroid. In other embodiments, the immunosuppressant is a small molecule (such as cyclosporine) or a monoclonal antibody (such as a cytokine blocker drug).
[0071] Nonsteroidal anti-inflammatory drugs (NSAIDs): A type of anti-inflammatory drug that acts by inhibiting the production of prostaglandins. NSAIDS have anti-inflammatory, analgesic and antipyretic effects. Examples of NSAIDS include ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salate, tolmetin and magnesium salicylate.
[0072] "Statistically significant" or "significant" means statistically significant, typically at least two standard deviations (2SD) away from the reference level. The term refers to statistical evidence that there is a difference. It is defined as the probability of making a decision to reject the null hypothesis when the null hypothesis is in fact true.
[0073] The term "co-administration" as used herein refers to administration of two or more treatments or two or more therapeutic agents (e.g., a GITR agonist and an additional anti-cancer therapy; or a GITR antagonist and an anti-autoimmune disease therapy) within a 24-hour period of each other, for example, as part of a clinical treatment regime; in other embodiments, "co-administration" refers to administration within 12 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 45 minutes, 30 minutes, 20 minutes, 15 minutes, 10 minutes, or 5 minutes; in other embodiments, "co-administration" refers to administration at the same time, either as part of a single formulation or as multiple formulations administered by the same or different routes. For example, when a GITR agonist and an additional anti-cancer therapy are administered in different pharmaceutical compositions or at different times, the routes of administration may be the same or different. For example, when a GITR antagonist and an additional anti-autoimmune disease therapy are administered in different pharmaceutical compositions or at different times, the routes of administration may be the same or different.
[0074] Binding properties of compounds to GITR / GITRL
[0075] In a particular embodiment, the present invention relates to compounds that bind to the glucocorticoid-induced receptor ligand (GITRL) by binding at the oligomer interface. The amino acid residues located at the interface of the GITRL oligomer have been described by Zhou et al. (PNAS, 2008) as having an affinity of 1000 nM or more, preferably 100 nM or more, more preferably 10 nM or more.
[0076] In certain embodiments, the present invention is directed to one of the aforementioned compounds, or a compound distinct from the aforementioned compounds, that exhibits affinity for wild-type GITRL that is at least about 10-fold greater than its affinity for human GITRL, binding to more than one of the amino acids selected from the group consisting of L42, L44, M71, I72, Q73, T74, K80, I81, Q82, N83, G86, T87, Y88, G114, I116, L118, N120, P121, Q122, F123, I124, and S125 of the wild-type GITRL sequence as follows:
[0077] MTLHPSPITCEFLFSTALISPKMCLSHLENMPLSHSRTQGAQRSSWKLWLFCSIVMLLFLCSFSWLIFIFLQLETAKEPCMAKFGPLPSKWQMASSEPPCVNKVSDWKLEILQNGLYLIYGQVAPNANYNDVAPFEVRLYKNKDMIQTLTNKSKIQNVGGTYELHVGDTIDLIFNSEHQVLKNNTYWGIILLANPQFIS (SEQ ID NO: 3)
[0078] The compound of the present invention binds to GITRL. Preferably, the compound binds to GITRL with an affinity (e.g., Kd) of 10 μM or less. Without limiting the disclosure, the binding activity can be determined by the binding of the compound to cells expressing GITRL on their cell surface, or the binding of the compound to purified or partially purified GITRL. The binding can be determined using, as a non-limiting example, native or recombinant GITRL, or a fragment thereof. The binding of the compound can be determined using methods well known to those skilled in the art. The preferred method for determining the binding activity of the compound to GITRL is surface plasmon resonance, isothermal titration calorimetry, ELISA, or microscale thermophoresis.
[0079] In a preferred embodiment, the compound exhibits at least about 10-fold greater binding to wild-type GITRL or a fragment thereof than the binding of the compound to a mutant or mutant fragment of GITRL. More preferred are compounds that exhibit about 100-fold greater binding to GITRL or a fragment thereof compared to the binding of the compound to a mutant or mutant fragment of GITRL. Most preferred are compounds that exhibit about 1000-fold greater binding to GITRL or a fragment thereof compared to the binding of the compound to a mutant or mutant fragment of GITRL.
[0080] Further preferred are compounds that exhibit the above-mentioned greater binding to wild-type GITRL or a fragment thereof compared to the corresponding mutant GITRL or a fragment thereof, the mutants having substitutions in amino acids selected from the group consisting of L42, L44, M71, I72, Q73, T74, K80, I81, Q82, N83, G86, T87, Y88, G114, I116, L118, N120, P121, Q122, F123, I124 and S125. Further preferred are mutants having substitutions at L114 to S125.
[0081] Small molecule modulators of GITR / GITRL
[0082] Compounds of formula (I)
[0083] In various embodiments, the present invention provides a compound of formula (I): [ka] , or a pharma- ceutically acceptable salt, ester or prodrug thereof; Is: R1 is hydrogen or an optionally substituted substituent; R2 is hydrogen or an optionally substituted substituent; R3 is hydrogen or an optionally substituted substituent; R4 is hydrogen or an optionally substituted substituent; R5 is hydrogen or an optionally substituted substituent; R6 is hydrogen or an optionally substituted substituent; R7 is hydrogen or an optionally substituted substituent; and R8 is hydrogen or an optionally substituted substituent; wherein any two or more of R1, R2, R3, R4, R5, R6, R7, or R8 may be bonded together to form one or more rings. In some embodiments, the optionally substituted substituents are halogen (e.g., F, Cl), —OH, —CN, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 cycloalkoxy, phenyl, 5- or 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, 4- to 7-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from O, S, and N, wherein each of alkyl, alkenyl, alkoxy, cycloaralkyl, cycloalkoxy, phenyl, heteroaryl, and heterocyclyl is selected from the group consisting of F, —OH, oxo (where applicable), C 1-4 Alkyl, Fluoro-Substituted C1-4 Alkyl, C 1-4 Alkoxy and Fluoro Substituted C 1-4 It may be optionally substituted with multiple, for example 1, 2 or 3, substituents independently selected from alkoxy.
[0084] In some embodiments, the present invention provides a compound of formula IB, or a pharma- ceutically acceptable salt, ester, or prodrug thereof. [ka] where: Ar 1 and Ar 2 are each independently an optionally substituted aryl (e.g., phenyl) or an optionally substituted heteroaryl (e.g., a 5- or 6-membered heteroaryl having 1 to 4 ring heteroatoms independently selected from O, S, and N). L 1 is a bond, optionally substituted C 1-6 An alkylene linker, -O-, -NH-, protected -NH-, or optionally substituted C 1-6 It is a heteroalkylene linker. In each description, G 1 is -OH, halogen (e.g., F), C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 cycloalkoxy, wherein each of alkyl, alkenyl, alkynyl, alkoxy and cycloalkoxy is optionally selected from -OH, -C 1-4 It may be optionally substituted with 1-3 substituents independently selected from alkyl and -F. m and n are each independently an integer of 0 to 3 (for example, 0, 1, or 2).
[0085] Typically, L in formula IB 1 is a bond. L 1 If is a bond, Ar 1and Ar 2 can be linked through any two available positions. In some embodiments, Ar 1 and Ar 2 are both six-membered aromatic rings, and preferably the linkage is 2 Ar 1 and / or Ar 1 In formula IB, Ar 2 In some embodiments, Ar 1 and Ar 2 are both six-membered aromatic rings, and preferably the linkage results in Ar 2 Ar 1 and / or Ar 1 In formula IB, Ar 2 It is para to the -NH group bonded to
[0086] In some embodiments, L in formula IB 1 is not a bond. For example, in some embodiments, L in formula IB 1 Ga-CH 2 -, -CH 2 CH 2 - and other unsubstituted linear C 1-6 In some embodiments, L in formula IB can be an alkylene linker. 1 is a non-substituted branch C 2-6 As used herein, an unsubstituted branched C 2 Alkylene is -CH(CH 3 In some embodiments, L in formula IB is to be understood as 1 In some embodiments, L in formula IB is -O-. 1 In some embodiments, L in formula IB is -NH- or a protected -NH-. 1 is an unsubstituted C containing 1 or 2 heteroatoms, which may be oxygen or nitrogen atoms; 1-6 For example, in some embodiments, L in formula IB can be a heteroalkylene linker.1 is -O-CH 2 -, -O-(CH 2 ) 2- , -O-(CH 2 ) 2 -O-, -NH-(CH 2 ) 2 In some embodiments, Ar may be -O-, etc. 1 and Ar 2 Both of the rings are six-membered aromatic rings, and L 1 Ar 1 and / or in formula IB, Ar 2 It may be para to the -NH- group attached to
[0087] In some embodiments, Ar 1 and Ar 2 may both be optionally substituted phenyl. In some embodiments, Ar 1 and Ar 2 may both be optionally substituted heteroaryls, such as a 5-membered heteroaryl having one heteroatom, such as thiophenyl or furanyl, a 6-membered heteroaryl having one or two nitrogen atoms, such as pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, or a 5-membered heteroaryl having two or three heteroatoms, such as oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, triazolyl, isoxazolyl, isothiazolyl. 1 and Ar 2 is optionally substituted phenyl, and Ar 1 and Ar 2 the other is an optionally substituted heteroaryl (e.g., a 5-membered heteroaryl having one heteroatom (e.g., thiophenyl or furanyl), a 6-membered heteroaryl having one or two nitrogen atoms (e.g., pyridyl, pyrimidyl, pyridazinyl, pyrazinyl), or a 5-membered heteroaryl having two or three heteroatoms (e.g., oxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, triazolyl, isoxazolyl, isothiazolyl, etc.).
[0088] In some embodiments, the “optionally substituted” aryl or heteroaryl groups herein (e.g., optionally substituted phenyl) can be unsubstituted or substituted with a halogen (e.g., F, Cl), —OH, —CN, —C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 cycloalkoxy, phenyl, 5- or 6-membered heteroaryl containing 1, 2 or 3 ring heteroatoms independently selected from O, S, and N, and 4- to 7-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from O, S, and N; wherein each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, phenyl, heteroaryl, and heterocyclyl optionally contains one or more, for example, 1, 2, or 3, of F, —OH, oxo (if applicable), C 1-4 Alkyl, Fluoro-Substituted C 1-4 Alkyl, C 1-4 Alkoxy and Fluoro Substituted C 1-4 It may be substituted with substituents independently selected from alkoxy.
[0089] As used herein, unless expressly stated to the contrary, combinations of substitutions and / or variables are permissible only if such combinations are chemically permissible and result in stable compounds. A "stable" compound is one which can be prepared and isolated and whose structure and properties remain essentially unchanged, or can be made to remain unchanged, for a period of time sufficient to permit use of the compound for the purposes described herein (e.g., therapeutic administration to a subject).
[0090] In some embodiments, m is 0. In some embodiments, n is 0. In some embodiments, m and n are both 0.
[0091] In some embodiments, at least one of m and n is not 0. In some embodiments, each occurrence of G 1 -OH, F, methyl, ethyl, CF 3 In some embodiments, m and n are both 1 and two G 1 The groups may be the same or different. If present, G 1 can be attached to any of the four ring carbons of the tetrahydrofuran ring.
[0092] In some embodiments, L in formula IB 1 is a bond, and the compound of formula IB can be characterized as having the following formula IB-1: [ka] Here, G 2 In each occurrence, -OH, halogen (e.g., F), CN, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 cycloalkoxy, wherein each of alkyl, alkenyl, alkynyl, alkoxy, and cycloalkoxy is optionally selected from -OH, -C 1-4 substituted with 1-3 substituents independently selected from alkyl and -F; p and q are each independently an integer from 0 to 4 (e.g., 0, 1, or 2); and G 1 , m, and n are defined below. In some embodiments, p is 0. In some embodiments, q is 0. In some embodiments, at least one of p and q is not 0. In some embodiments, both p and q are 0. In some embodiments, each occurrence of G 2 are independently -OH, F, Cl, Br, I, CN, 1-3 fluorine or C optionally substituted with cyclopropyl or cyclobutyl; 1-4 C optionally substituted with alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc.), 1-3 fluorine, or cyclopropoxy or cyclobutoxy 1-4 It may be substituted with alkoxy (eg, methoxy, ethoxy, etc.). In some embodiments, m is 0. In some embodiments, n is 0. In some embodiments, m and n are both 0. In some embodiments, at least one of m and n is not 0. In some embodiments, each occurrence of G 1 -OH, F, methyl, ethyl, CF 3 In some embodiments, m and n are both 1 and two G 1 The groups can be the same or different.
[0093] In some embodiments, m and n are both 0, and the compound of formula IB can be characterized as having formula IB-2: [ka] In the formula, G 2 , p and q are defined herein. In some embodiments, p is 0. In some embodiments, both p and q are 0. In some embodiments, q is 0. In some embodiments, at least one of p and q is not 0. In some embodiments, p and q are the same. In some embodiments, p and q are different. In some embodiments, p can be 0, 1, 2, or 3. In some embodiments, q can be 0, 1, 2, or 3. In some embodiments, each occurrence of G 2 C, which may be independently substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy; 1-4 C optionally substituted with alkoxy (e.g., methoxy, ethoxy, etc.), 1 to 3 fluorine, cyclopropyl, or cyclobutyl 1-4 It may be alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc.), -OH, F, Cl, Br, I, or CN.
[0094] The compounds described herein may contain one or more asymmetric centers and therefore may exist in various isomeric forms, e.g., enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric synthesis. For example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present disclosure further includes the compounds described herein as individual isomers substantially free of other isomers or as mixtures of various isomers, including racemic mixtures.
[0095] In some embodiments, the compound of Formula (I) is: [ka]
[0096] Compound of formula (II)
[0097] In various embodiments, the present invention provides a compound of formula (II): [ka] , or a pharma- ceutically acceptable salt, ester or prodrug thereof; where: R 9 is hydrogen or an optionally substituted substituent; R 10 is hydrogen or an optionally substituted substituent; R 11 is hydrogen or an optionally substituted substituent; R 12is hydrogen or an optionally substituted substituent; R 13 is hydrogen or an optionally substituted substituent; R 14 is hydrogen or an optionally substituted substituent; R 15 is hydrogen or an optionally substituted substituent R 16 is hydrogen or an optionally substituted substituent; In the formula, R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , or R 16 Any two or more of may be linked together to form one or more rings. In some embodiments, the optionally substituted substituents are halogen (e.g., F, Cl), —OH, —CN, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 cycloalkoxy, phenyl, 5- or 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, and 4- to 7-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from O, S, and N, where each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, phenyl, heteroaryl, and heterocyclyl is independently selected from F, -OH, oxo (where applicable), C 1-4 Alkyl, Fluoro-Substituted C 1-4 Alkyl, C 1-4 Alkoxy, fluoro-substituted C 1-4 It is optionally substituted with one or more, for example 1, 2, or 3, substituents independently selected from alkoxy.
[0098] In some embodiments, the present invention provides a compound of formula II-B, or a pharma- ceutically acceptable salt, ester, or prodrug thereof; [ka] where: L 10 is optionally substituted C 1-10 Alkylene Linker, Optionally Substituted C 3-10 Cycloalkylene linker, optionally substituted phenylene, optionally substituted heteroarylene, optionally substituted C 1-10 a heteroalkylene linker, or an optionally substituted heterocyclylene; G 10 and G 11 are independently hydrogen or optionally substituted C 1-4 is alkyl, p and q are independently integers from 0 to 4 (e.g., 0, 1, 2); G 20 represents, at each occurrence, halogen (e.g., F, Cl), -OH, -CN, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 and cycloalkoxy, phenyl, 5- or 6-membered heteroaryl containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, and 4- to 7-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from O, S, and N, wherein each of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkoxy, phenyl, heteroaryl, and heterocyclyl is optionally selected from F, -OH, oxo (where applicable), C, -C, -O, -O- ... 1-4 Alkyl, Fluoro-Substituted C 1-4 Alkyl, C 1-4 Alkoxy and fluoro substituted C 1-4 It may be substituted with one or more (eg, 1, 2, or 3) substituents independently selected from alkoxy.
[0099] In some embodiments, L in formula II-B 10 But, substituted linear C 1-10 Alkylene (e.g., C 3-6 alkylene) linker or unsubstituted branched C 1-10 Unsubstituted C, such as alkylene linkers 1-10 It is an alkylene linker.
[0100] In some embodiments, G 10 and G 11 In some embodiments, both of G 10 and G 11 are independently hydrogen or C 1-4 Alkyl (for example, methyl, ethyl, n-propyl, isopropyl, etc.).
[0101] In some embodiments, p is 0. In some embodiments, both p and q are 0. In some embodiments, q is 0. In some embodiments, at least one of p and q is not 0. In some embodiments, p and q are the same. In some embodiments, p and q are different. In some embodiments, p can be 0, 1, 2, or 3. In some embodiments, q can be 0, 1, 2, or 3. In some embodiments, each occurrence of G 20 C, which is optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy; 1-4 C optionally substituted with alkoxy (e.g., methoxy, ethoxy, etc.), 1-3 fluorine, cyclopropyl, cyclobutyl 1-4 It may be alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc.), -OH, F, Cl, Br, I, or CN.
[0102] In some embodiments, the compound of formula (II) is: [ka]
[0103] Non-limiting embodiments of compounds of the present invention are provided in Table 1 herein.
[0104] Table 1:. GITR and GITRL receptor complex modulators [Table 1]
[0105] As used herein, the term "alkyl" refers to a straight or branched chain saturated aliphatic group having a chain of carbon atoms. x Alkyl and C x -C y Alkyl is typically used where X and Y indicate the number of carbon atoms in the chain. For example, C 1 -C 6 Alkyl includes alkyls having 1 to 6 carbon chains (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, etc.). Alkyl represented along with another group (e.g., as in arylalkyl) refers to a linear or branched saturated alkyl divalent radical having the number of atoms indicated, or, when no atoms are indicated, refers to a bond, e.g., (C 6 -C 10 )Aryl(C 0 -C 3 ) Alkyl includes phenyl, benzyl, phenethyl, 1-phenylethyl-3-phenylpropyl, and the like. The alkyl backbone can be optionally interrupted with one or more heteroatoms, such as N, O or S.
[0106] In a preferred embodiment, a straight or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1 ~C 30 , C for branched chains 3 ~C 30), and more preferably no more than 20. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure. As used throughout the specification, examples, and claims, the term "alkyl" (or "lower alkyl") is intended to include both "unsubstituted alkyls" and "substituted alkyls," the latter of which refers to alkyl moieties having one or more substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
[0107] Unless the carbon number is otherwise specified, "lower alkyl" as used herein means an alkyl group as defined above, but having 1 to 10 carbon atoms in its backbone, more preferably 1 to 6 carbon atoms. Similarly, "lower alkenyl" and "lower alkynyl" have similar chain lengths. Throughout this application, preferred alkyl groups are lower alkyls. In preferred embodiments, a substituent referred to herein as alkyl is a lower alkyl.
[0108] Non-limiting examples of substituents of substituted alkyls can include halogen, hydroxy, nitro, thiol, amino, azido, imino, amide, phosphoryl (including phosphonates and phosphinates), sulfonyl (including sulfates, sulfonamides, sulfamoyl and sulfonates), and silyl groups, as well as ethers, alkylthio, carbonyl (including ketones, aldehydes, carboxylates and esters), -CF, -CN, and the like.
[0109] As used herein, the term "alkenyl" refers to an unsaturated straight-chain, branched-chain, or cyclic hydrocarbon group having at least one carbon-carbon double bond. x Alkenyl and C x -C y Alkenyl is typically used where X and Y indicate the number of carbon atoms in the chain. For example, C 2 -C 6Alkenyl includes alkenyl having a chain of 2 to 6 carbons and at least one double bond, such as vinyl, allyl, propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, etc. Alkenyl represented with another radical (such as in arylalkenyl) refers to a straight or branched alkenyl divalent radical having the number of atoms indicated. The backbone of the alkenyl can be optionally inserted with one or more heteroatoms such as N, O, or S.
[0110] The term "alkynyl," as used herein, refers to an unsaturated hydrocarbon group having at least one carbon-carbon triple bond. C x Alkynyl and C x -C y Alkynyl is typically used where X and Y indicate the number of carbon atoms in the chain. For example, C 2 -C 6 Alkynyl includes alkynyl having a chain of 2 to 6 carbons and at least one triple bond, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, isopentynyl, 1,3-hexa-diyn-yl, n-hexynyl, 3-pentynyl, 1-hexen-3-ynyl, etc. Alkynyl shown together with another group (e.g., as in arylalkynyl) refers to a straight or branched alkynyl divalent group having the indicated number of atoms. The alkynyl backbone can be optionally inserted with one or more heteroatoms such as N, O, or S.
[0111] The terms "alkylene," "alkenylene," and "alkynylene" refer to divalent alkyl, alkenyl, and alkynyl groups. x and C x -C y Typically, X and Y are used to indicate the number of carbon atoms in the chain. For example, C 1 -C 6 Alkylene includes methylene (-CH 2 -), ethylene (-CH 2 CH 2-), trimethylene (-CH 2 CH 2 CH 2 -), tetramethylene (-CH 2 CH 2 CH 2 CH 2 -), 2-methyltetramethylene (-CH 2 CH(CH 3 )CH 2 CH 2 -), pentamethylene (-CH 2 CH 2 CH 2 CH 2 CH 2 -) and others.
[0112] As used herein, the term "alkylidene" refers to a group having the general formula =CR a R b R means a linear or branched unsaturated aliphatic divalent group having the formula a and R b Non-limiting examples of C are each independently hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl. x Alkylidene and C x -C y Alkylidene is typically used where X and Y indicate the number of carbon atoms in the chain. For example, C 2 -C 6 Alkylidene is methylidene (=CH 2 ), ethylidene (=CHCH 3 ), isopropylidene (=C(CH 3 ) 2 ), Propylene (=CHCH 2 CH 3 ), arylidene (=CH-CH=CH 2 ) etc.
[0113] The term "heteroalkyl" as used herein refers to a straight or branched chain or cyclic carbon-containing group, or combinations thereof, containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, Se, B, and S, where the phosphorus and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. Heteroalkyl can be substituted for alkyl groups as defined above.
[0114] As used herein, the term "halogen" or "halo" refers to an atom selected from fluorine, chlorine, bromine, and iodine, and the term "halogen radioisotope" or "haloisotope" refers to a radioactive nuclide of an atom selected from fluorine, chlorine, bromine, and iodine.
[0115] As an isolated group or part of a larger group, "halogen-substituted moiety" or "halo-substituted moiety," as that term is used herein, means an aliphatic, alicyclic, or aromatic moiety, as described herein, that is substituted with one or more "halo" atoms. For example, halo-substituted alkyl includes haloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl, etc. (e.g., halo-substituted (C 1 -C 3 )Alkyl includes chloromethyl, dichloromethyl, difluoromethyl, and trifluoromethyl (-CF 3 ), 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-1,1-dichloroethyl, etc.
[0116] The term "aryl" refers to a monocyclic, bicyclic, or tricyclic fused aromatic ring system. x Aryl and C x -C y Aryl is used where X and Y indicate the number of carbon atoms in the ring system. For example, C 6 -C 12 Aryl includes aryl having 6 to 12 carbon atoms in the ring system. Examples of aryl groups include: Pyridinyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrazolyl, pyridazinyl, pyrazinyl, triazinyl, Tetrazolyl, indolyl, benzyl, phenyl, naphthyl, anthracenyl, azulenyl, fluorenyl, indanyl, indenyl, Naphthyl, phenyl, tetrahydronaphthyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, Benztriazolyl, benztetraazolyl, benzisooxazolyl, benzisothiazolyl, benzimidazolyl, carbazolyl, 4aH carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3b]tetrahydrofuran, furanyl, furanzanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, Indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, Phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperidinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, Purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, Pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinoclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, Examples include, but are not limited to, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, and xanthenyl. In some embodiments, 1, 2, 3, or 4 hydrogen atoms on each ring can be replaced by a substituent.
[0117] The term "heteroaryl" refers to an aromatic 5-8 membered monocyclic, 8-12 membered fused bicyclic, or 11-14 membered fused tricyclic ring system having 1-3 heteroatoms in the monocyclic, 1-6 heteroatoms in the bicyclic, or 1-9 heteroatoms in the tricyclic, said heteroatoms being selected from O, N, or S (e.g., 1-3, 1-6, or 1-9 carbon atoms and N, O, or S heteroatoms in the monocyclic, bicyclic, or tricyclic, respectively). x Heteroaryl and C x -C y In heteroaryl, X and Y are used to indicate the number of carbon atoms in the ring system. For example, C 4- C 9 Heteroaryl includes heteroaryls having from 4 to 9 carbon atoms in the ring system. Heteroaryls include: Benzo[b]furan, benzo[b]thiophene, benzimidazole, imidazo[4,5-c]pyridine, quinazoline, thieno[2,3-c]pyridine, thieno[3,2-b]pyridine, thieno[2,3-b]pyridine, indolizine, imidazo[l,2a]pyridine, Quinoline, isoquinoline, phthalazine, quinoxaline, naphthyridine, quinolizine, indole, isoindole, indazole, indoline, Benzoxazole, benzopyrazole, benzothiazole, imidazo[l,5-a]pyridine, pyrazolo[l,5-a]pyridine, imidazo[l,2-a]pyrimidine, imidazo[l,2-c]pyrimidine, imidazo[l,5-a]pyrimidine, imidazo[l,5-c]pyrimidine, pyrrolo[2,3-b]pyridine, Pyrrolo[2,3-c]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine, pyrrolo[2,3-d]pyrimidine, pyrrolo[3,2-d]pyrimidine, pyrrolo[2,3-b]pyrazine, pyrazolo[1,5-a]pyridine, pyrrolo[1,2-b]pyridazine, pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrimidine, Pyrrolo[1,2-a]pyrazine, triazo[1,5-a]pyridine, pteridine, purine, carbazole, acridine, phenazine, phenothiazene, phenoxazine, 1,2-dihydropyrrolo[3,2-1-hi]indole, Indolizine, pyrido[1,2-a]indole, 2(1H)-pyridinone, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzothiazolyl, Benzotriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, Cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, Indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxepanyl, oxetanyl, oxindolyl, pyrimidinyl, phenanthrinidinyl, Phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, Piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, Pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinoclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl, Examples include, but are not limited to, those derived from thiophenyl and xanthenyl. Some exemplary heteroaryl groups include, but are not limited to, pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, pyridazinyl, pyrazinyl, quinolinyl, indolyl, thiazolyl, naphthyridinyl, 2-amino-4-oxo-3,4-dihydropteridin-6-yl, tetrahydroisoquinolinyl, etc. In some embodiments, 1, 2, 3, or 4 hydrogen atoms of each ring may be replaced by a substituent.
[0118] The term "cyclyl" or "cycloalkyl" refers to saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, such as 3 to 8 carbons, and for example 3 to 6 carbons. x Cyclyl and C x -C y Cyclyl is typically used where X and Y indicate the number of carbon atoms in the ring system. For example, C 3 -C 8 Cyclyl includes cyclyls having 3 to 8 carbon atoms in the ring system. Cycloalkyl groups may be further substituted, for example, with 1, 2, 3, or 4 substituents. 3 -C 10 Cyclyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,5-cyclohexadienyl, cycloheptyl, cyclooctyl, bicyclo[2.2.2]octyl, adamantan-l-yl, decahydronaphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 2-oxobicyclo[2.2.1]hept-l-yl, and the like.
[0119] Aryl and heteroaryl can be, for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphate, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moiety, -CF 3 It may be optionally substituted at one or more positions with one or more substituents such as -, -CN.
[0120] The term "heterocyclyl" refers to a non-aromatic 4-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms in the monocyclic, 1-6 heteroatoms in the bicyclic, or 1-9 heteroatoms in the tricyclic, the heteroatoms being selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S in the monocyclic, bicyclic, or tricyclic ring, respectively).x Heterocyclyl and C x -C y Heterocyclyl is typically used where X and Y indicate the number of carbon atoms in the ring system. For example, C 4 -C 9 Heterocyclyl includes heterocyclyl having 4-9 carbon atoms in the ring system. In some embodiments, 1, 2, or 3 hydrogen atoms of each ring can be replaced by a substituent. Exemplary heterocyclyl groups include, but are not limited to, piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, piperidyl, 4-morpholyl, 4-piperazinyl, pyrrolidinyl, perhydropyrrolidinyl, 1,4-diazaperhydroepynyl, 1,3-dioxanyl, 1,4-dioxanyland, and the like.
[0121] The terms "bicyclic" and "tricyclic" refer to fused, bridged or joined by single-bonded polycyclic ring assemblies.
[0122] The term "cyclylalkylene" refers to a divalent aryl, heteroaryl, cyclyl, or heterocyclyl.
[0123] As used herein, the term "fused ring" refers to a ring that is connected to another ring to form a compound having a bicyclic structure when ring atoms common to both rings are directly bonded to each other. Non-limiting examples of common fused rings include decalin, naphthalene, anthracene, phenanthrene, indole, furan, benzofuran, quinoline, etc. Compounds having fused ring systems can be saturated, partially saturated, cyclyl, heterocyclyl, aromatic, heteroaromatic, etc.
[0124] The term "carbocyclyl," used alone or in combination with another group, refers to a monocyclic, bicyclic, or tricyclic structure of 3 to 14 carbon atoms. In some embodiments, one or more of the hydrogen atoms of the carbocyclyl may be optionally replaced by a substituent.
[0125] "Carbocycle" refers to a fully saturated ring system, a saturated ring system, a partially saturated ring system, an aromatic ring system, a non-aromatic ring system, an unsaturated ring system, or a partially unsaturated ring system, and "carbocycle" refers to a monocyclic, bicyclic, polycyclic, spirocyclic, fused, bridged, or linked ring system. In some embodiments, one or more of the hydrogen atoms of a carbocycle may be optionally replaced by a substituent. In some embodiments, a carbocycle optionally contains one or more heteroatoms. In some embodiments, the heteroatoms are selected from N, O, S, or P.
[0126] The terms "cyclic", "cyclic group" and "ring" or "rings" refer to a carbocyclic ring which may be fully saturated, saturated, partially saturated, unsaturated, partially unsaturated, non-aromatic or aromatic, substituted or unsubstituted, and which may optionally contain one or more heteroatoms. In some embodiments, the heteroatoms are selected from N, O, S, or P, and in some embodiments, one or more of the hydrogen atoms of the ring may be optionally replaced by a substituent. In some embodiments, the ring may be monocyclic, bicyclic, polycyclic, spirocyclic, fused, bridged, or linked.
[0127] The term "spirocycloalkyl" (spiro) means a spiro ring, where the ring is linked to the molecule via a carbon atom and the resulting carbocyclic ring is formed by an alkylene group. 3 -C 8 The term "spiro-cycloalkyl" (spiro) means a 3-8 membered spiro ring, where the ring is linked to the molecule via a carbon atom and the resulting 3-8 membered carbocyclic ring is formed by an alkylene group having 2 to 7 carbon atoms. 5 "-cycloalkyl" (spiro) means a five-membered spiro ring in which the ring is linked to the molecule via a carbon atom such that the resulting five-membered carbocyclic ring is formed by an alkylene group having four carbon atoms.
[0128] The term "spirocycloalkenyl" (spiro) means a spirocyclic ring, where the ring is linked to the molecule via a carbon atom and the resulting carbocyclic ring is formed by an alkenylene group. 3 -C 8The term "spiro-cycloalkenyl" (spiro) means a 3-8 membered ring, where the ring is linked to the molecule via a carbon atom and the resulting 3-8 membered carbocyclic ring is formed by an alkenylene group having 2 to 7 carbon atoms. 5 "-cycloalkenyl" (spiro) means a five-membered ring, the ring being linked to the molecule via a carbon atom such that the resulting five-membered carbocyclic ring is formed by an alkenylene group having four carbon atoms.
[0129] The term "spiroheterocyclyl" (spiro) refers to a saturated or unsaturated spirocyclyl ring, the ring may be linked to the molecule through a carbon atom or, if present, through a nitrogen atom. In some embodiments, the heteroatom is selected from O, N, S, or P. In some embodiments, the heteroatom is O, S, or N. The term "spiro-C 3 -C 8 -heterocyclyl" (spiro) means a 3-8 membered, saturated or unsaturated spirocyclyl ring, which may be linked to the molecule through a carbon atom or, if a nitrogen atom is present, through a nitrogen atom. In some embodiments, the heteroatom is selected from O, N, S, or P. In some embodiments, the heteroatom is O, S, or N. The term "spiro-C 5 "(spiro)" means a 5-membered, saturated or unsaturated spirocyclic ring, which can contain one or more heteroatoms that can be attached to the molecule through a carbon atom or, optionally, a nitrogen atom, if present. In some embodiments, the heteroatoms are selected from O, N, S, or P, and in some embodiments, the heteroatoms are O, S, or N.
[0130] In some embodiments, one or more of the hydrogen atoms of the spirocyclic ring may be optionally replaced by a substituent. In some embodiments, one or more of the hydrogen atoms of the spirocycloalkyl may be optionally replaced by a substituent. In some embodiments, the spiro-C 3 -C 8One or more hydrogen atoms of the -cycloalkyl may be optionally replaced by a substituent. 5 One or more hydrogen atoms of the -cycloalkyl may be optionally replaced by a substituent. In some embodiments, one or more hydrogen atoms of the spirocycloalkenyl may be optionally replaced by a substituent. In some embodiments, the spiro-C 3 -C 8 One or more hydrogen atoms of the -cycloalkenyl may be optionally replaced by a substituent. 5 One or more hydrogen atoms of the -cycloalkenyl may be optionally replaced by a substituent. In some embodiments, one or more hydrogen atoms of the spiro-heterocycyl may be optionally replaced by a substituent. In some embodiments, the spiro-C 3 -C 8 One or more hydrogen atoms of the -heterocycle may be optionally replaced by a substituent. 5 One or more hydrogen atoms of the heterocycle may be optionally replaced by a substituent.
[0131] The term "carbonyl" as used herein refers to the group -C(O)-. It is noted that the carbonyl group can be further substituted with a variety of substituents to form different carbonyl groups including acids, acid halides, amides, esters, ketones, and the like.
[0132] The term "carboxy" refers to the radical -C(O)O-. It is noted that compounds described herein containing a carboxy moiety can include protected derivatives thereof, i.e., where the oxygen is replaced with a protecting group. Suitable protecting groups for carboxy moieties include benzyl, tert-butyl, and the like. The term "carboxyl" refers to -COOH.
[0133] The term "cyano" refers to the group --CN.
[0134] The term "heteroatom" refers to an atom that is not a carbon atom, and specific examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and the halogens, and a "heteroatom moiety" includes a moiety where the atom to which the moiety is attached is not a carbon. Examples of heteroatom moieties include -N=, -NR N -, -N + (O - )=, -O-, -S- or -S(O) 2 -, -OS(O) 2 - and -SS-, where R N is H or a further substituent.
[0135] The term "hydroxyl" means the group -OH.
[0136] "Imine derivative" means a derivative containing the moiety -C(NR)-, where R contains a hydrogen or carbon atom alpha to the nitrogen.
[0137] The term "nitro" refers to the group -NO 2 means...
[0138] "Oxaaliphatic", "oxaalicyclic" or "oxaaromatic" means aliphatic, alicyclic, or aromatic, except where one or more oxygen atoms (-O-) are positioned between the respective carbon atoms of the aliphatic, alicyclic, or aromatic.
[0139] As defined herein, "oxoaliphatic," "oxocycloaliphatic," or "oxoaromatic" means an aliphatic, alicyclic, or aromatic group substituted with a carbonyl group, which may be an aldehyde, ketone, ester, amide, acid, or acid halide.
[0140] As used herein, the term "oxo" refers to the substituent ═O.
[0141] As used herein, the term "aromatic" refers to a ring system whose constituent atoms are unsaturated and in which all atoms in the ring system are sp 2It refers to a moiety that is hybridized and has a total number of pi electrons equal to 4n + 2. An aromatic ring can be such that the ring atoms are only carbon atoms (e.g., aryl) or can include carbon and non-carbon atoms (e.g., heteroaryl).
[0142] As used herein, the term "substituted" refers to the independent replacement of one or more (typically 1, 2, 3, 4, or 5) of the hydrogen atoms on the substituted moiety with a substituent independently selected from the group of substituents listed below in the definition of "substituent." In general, a non-hydrogen substituent may be any substituent that may be bound to an atom of a given moiety that is specified to be substituted. Examples of the substituent include: Acyl, acylamino, acyloxy, aldehyde, alicyclic, aliphatic, alkanesulfonamido, alkanesulfonyl, alkaryl, alkenyl, Alkoxy, alkoxycarbonyl, alkyl, alkylamino, alkylcarbanoyl, alkylene, alkylidene, alkylthio, alkynyl, amide, Amido, amino, amidine, aminoalkyl, aralkyl, aralkylsulfonamide, arenesulfonamide, arenesulfonyl, aromatic, aryl, Arylamino, arylcarbanoyl, aryloxy, azido, carbamoyl, carbonyl, carbonyl(s) including ketone, carboxy, carboxylate, CF 3 , cyano (CN), cyanoalkyl, cycloalkylene, ester, ether, haloalkyl, halogen, halogen, heteroaryl, heterocyclyl, Hydroxy, hydroxyalkyl, imino, imino ketone, ketone, mercapto, nitro, oxaalkyl, oxo, oxoalkyl, Examples of substituents include, but are not limited to, phosphoryl (including phosphonates and phosphinates), silyl groups, sulfonamides, sulfonyls (including sulfates, sulfamoyls, and sulfonates), thiols, and ureido moieties, each of which may also be optionally substituted. In some cases, two substituents may be combined with the carbons to which they are attached to form a ring. In some cases, two or more substituents may be combined with the carbons to which they are attached to form one or more rings.
[0143] Substituents can be optionally protected using any of the protecting groups commonly used in the art. Non-limiting examples of protecting groups can be found, for example, in Greene and Wuts, Protective Groups in Organic Synthesis, 44 th Ed., Wiley & Sons, 2006.
[0144] The term "alkoxyl" or "alkoxy" as used herein refers to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, and the like. An "ether" is two hydrocarbons covalently linked by an oxygen. Thus, an alkyl substituent in which an ether is an alkoxyl or similar can be represented by one of -O-alkyl, -O-alkenyl, and -O-alkynyl. Aryloxy can be represented by -O-aryl or -O-heteroaryl, where aryl and heteroaryl are as defined below. The alkoxy and aroxy groups may be substituted as described above for alkyl.
[0145] The term "aralkyl," as used herein, refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group).
[0146] The term "alkylthio" refers to an alkyl group, as defined above, having a sulfur group attached thereto. In preferred embodiments, the "alkylthio" moiety is represented by one of -S-alkyl, -S-alkenyl, and -S-alkynyl. Representative alkylthio groups include methylthio, ethylthio, and the like. The term "alkylthio" also encompasses cycloalkyl groups, alkene and cycloalkene groups, and alkyne groups. "Arylthio" refers to an aryl or heteroaryl group.
[0147] The term "sulfinyl" refers to the group -SO-. It is noted that the sulfinyl radical can be further substituted with a variety of substituents to form different sulfinyl groups including sulfinic acids, sulfinamides, sulfinyl esters, sulfoxides, and the like.
[0148] The term "sulfonyl" refers to the group -SO 2 The sulfonyl group is a sulfonic acid (-SO 3 It is noted that the sulfonyl groups can be further substituted with a variety of substituents to form different sulfonyl groups including sulfonamides, sulfonate esters, sulfonate salts, and the like.
[0149] The term "thiocarbonyl" refers to the group -C(S)-. It is noted that the thiocarbonyl group can be further substituted with a variety of substituents to form different thiocarbonyl groups including thioacids, thioamides, thioesters, thioketones, and the like.
[0150] As used herein, the term "amino" refers to -NH 2 The term "alkylamino" refers to a nitrogen moiety having at least one straight or branched unsaturated aliphatic, cyclyl, or heterocyclyl radical attached to the nitrogen. Representative amino groups include -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -NH(C 1 -C 10 alkyl), -NH(C1 -C 10 Alkyl) 2 The term "alkylamino" includes "alkenylamino", "alkynylamino", "cyclylamino", and "heterocyclylamino". The term "arylamino" refers to a nitrogen moiety having at least one aryl radical attached to the nitrogen. For example, -NHaryl and -N(aryl) 2 "Heteroarylamino" means a nitrogen moiety having at least one heteroaryl radical attached to the nitrogen. For example, -NHheteroaryl and -N(heteroaryl) 2 Optionally, the two substituents taken together with the nitrogen can also form a ring. Unless otherwise indicated, compounds described herein that contain an amino moiety can include protected derivatives thereof. Suitable protecting groups for amino moieties include acetyl, tertbutoxycarbonyl, benzyloxycarbonyl, and the like.
[0151] The term "aminoalkyl" refers to alkyl, alkenyl, and alkynyl as defined above, except that one or more substituted or unsubstituted nitrogen atoms (-N-) are positioned between the carbon atoms of the alkyl, alkenyl, or alkynyl. For example, (C 2 -C 6 ) Aminoalkyl refers to a chain containing 2-6 carbons and one or more nitrogen atoms positioned between the carbon atoms.
[0152] The term "alkoxyalkoxy" refers to -O-(alkyl)-O-(alkyl), e.g., -OCH 2 CH 2 OCH 3 etc.
[0153] The term "alkoxycarbonyl" refers to -C(O)O-(alkyl), e.g., -C(=O)OCH 3 , -C(=O)OCH 2 CH 3 etc.
[0154] The term "alkoxyalkyl" refers to -(alkyl)-O-(alkyl), e.g., -CH 2 OCH 3 , -CH 2 OCH 2 CH 3 etc.
[0155] The term "aryloxy" refers to -O-(aryl), for example, -O-phenyl, -O-pyridinyl, and the like.
[0156] The term "arylalkyl" refers to -(alkyl)-(aryl), such as benzyl (i.e., -CH 2 Phenyl), -CH 2 -pyrindinyl, etc.
[0157] The term "arylalkyloxy" refers to -O-(alkyl)-(aryl), such as -O-benzyl, -O-CH 2 -pyridinyl, etc.
[0158] The term "cycloalkyloxy" refers to -O-(cycloalkyl), such as -O-cyclohexyl.
[0159] The term "cycloalkylalkyloxy" refers to -O-(alkyl)-(cycloalkyl), e.g., -OCH 2 Cyclohexyl, etc.
[0160] The term "aminoalkoxy" refers to -O-(alkyl)-NH 2 , e.g. -OCH 2 NH 2 , -OCH 2 CH 2 NH 2 etc.
[0161] The term "mono- or dialkylamino" refers to -NHCH 3 , -N(CH 3 ) 2 and the like means -NH(alkyl) or -N(alkyl)(alkyl).
[0162] The term "mono- or dialkylaminoalkoxy" refers to -O-(alkyl)-NH(alkyl) or -O-(alkyl)-N(alkyl)(alkyl), e.g., -OCH 2 NHCH 3 , -OCH 2 CH 2 N(CH 3 ) 2 etc.
[0163] The term "arylamino" means -NH(aryl), such as -NH-phenyl, -NH-pyridinyl, and the like.
[0164] The term "arylalkylamino" refers to -NH-(alkyl)-(aryl), such as -NH-benzyl, -NHCH 2 -pyridinyl, etc.
[0165] The term "alkylamino" refers to -NH(alkyl), e.g., -NHCH 3 , -NHCH 2 CH 3 etc.
[0166] The term "cycloalkylamino" means -NH-(cycloalkyl), such as -NH-cyclohexyl.
[0167] The term "cycloalkylalkylamino" refers to -NH-(alkyl)-(cycloalkyl), e.g., -NHCH 2 -cyclohexyl, etc.
[0168] Commonly used abbreviations are Me for methyl, Et for ethyl, Ph for phenyl, and t-Bu for tert-butyl.
[0169] It should be noted that with respect to all of the definitions provided herein, the definitions should be construed as open ended in the sense that additional substituents beyond those specified may be included. 1Alkyl indicates the presence of one carbon atom but does not indicate what the substituents on the carbon atom are. Thus, C 1 Alkyl is methyl (i.e., -CH 3 ) and -CR a R b R c where R a , R b , and R c may each independently be hydrogen or any other substituent where the atom α to the carbon is a heteroatom or cyano. Therefore, CF 3 , C.H. 2 OH and CH 2 CN is all C 1 It is an alkyl.
[0170] Unless otherwise stated, structures depicted herein are meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, the replacement of a hydrogen atom with deuterium or tritium, or the replacement of a carbon atom with 13 C- or 14 Compounds having this structure, except for substitution by a C-enriched carbon, are within the scope of this invention.
[0171] Synthetic preparation. In various embodiments, the compounds of the present invention disclosed by the present invention can be synthesized using any synthetic method available to those skilled in the art. In various embodiments, the compounds of the present invention disclosed by the present invention can be prepared in various ways known to those skilled in the art of organic synthesis and similar to the exemplary compounds whose synthesis is described herein. The starting materials used in preparing these compounds may be commercially available or may be prepared by known methods. Preparation of the compounds may include protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be easily determined by those skilled in the art. The chemistry of protecting groups can be found, for example, in Greene and Wuts, Protective Groups in Organic Synthesis, 44th Ed., Wiley & Sons, 2006, which is incorporated herein by reference in its entirety. Non-limiting examples of synthetic methods used to prepare various embodiments of the compounds of the present invention are disclosed in the Examples section of this specification. The reactions of the processes described herein can be carried out in suitable solvents that can be easily selected by those skilled in the art of organic synthesis. A suitable solvent may be substantially non-reactive with the starting materials (reactants), intermediates, or products at the temperature at which the reaction is carried out, i.e., a temperature that may range from the freezing temperature of the solvent to the boiling point of the solvent. A given reaction may be carried out in one solvent or a mixture of two or more solvents. Depending on the particular reaction step, a suitable solvent for a particular reaction step may be selected.
[0172] Use in polymers. In various embodiments, the compound of the present invention as disclosed herein can be bound to a polymer matrix, for example, for controlled delivery of the compound.The compound can be conjugated via covalent or non-covalent bonds.In certain embodiments where the compound is covalently bound to the polymer matrix, the bond can include a moiety (e.g., ester, amide, carbonate, carbamate, imide, etc.) that can be cleaved under biological conditions. In certain embodiments, the conjugate compound may be a pharma- ceutically acceptable salt, ester, or prodrug of a compound disclosed herein. Compounds as disclosed herein may be associated with any type of polymer matrix known in the art for delivery of therapeutic agents.
[0173] Agonists of the GITR / GITRL receptor complex
[0174] The present invention further provides peptide agonists of GITR. In one embodiment, a peptide agonist of GITR comprises, consists of, or consists essentially of a peptide having the sequence set forth in SEQ ID NO:1, or a mutant or functional equivalent thereof.
[0175] GAMASQLETAKEPCMAKFGPLPSKWQMASSEPPCVNKVSDWKLEILQNGLYLIYGQVAPNANYNDVAPFEVRLYKNKDMIQTLTNKSKIQNVGGTYELHVGD TIDLIFNSEHQVLKNNTYWGIILLANPQFIS(GSGSGSGS)nKEPCMAKFGPLPSKWQMASSEPPCVNKVSDWKLEILQNGLYLIYGQVAPNANYNDVAPFE VRLYKNKDMIQTLTNKSKIQNVGGTYELHVGDTIDLIFNSEHQVLKNNTYWGIILLANPQFIS(GSGSGSGS)nKEPCMAKFGPLPSKWQMASSEPPCVNKVSDWKLEILQNGLYLIYGQVAPNANYNDVAPFEVRLYKNKDMIQTLTNKSKIQNVGGTYELHVGDTIDLIFNSEHQVLKNNTYWGIILLANPQFIS (SEQ ID NO: 1), where n = 1 to 4.
[0176] In another embodiment, the peptide agonist of GITR has the sequence KEPCMAKFGPLPSKWQMASSEPPCVNKVSDWKLEILQNGLYLIYGQVAPNANYNDVAPFEVRLYKNKDMIQTLTNKSKIQNVGGTYELHVGDTIDLIFNSEHQVLKNNTYWGIILLANPQFIS (SEQ ID NO: 4) The peptide may comprise, consist of, or consist essentially of a peptide having the following structure: A functional GITR is an oligomer. A peptide comprising, consisting of, or consisting essentially of the sequence of SEQ ID NO: 4 binds to a monomer of a functional GITR oligomer (eg, a trimer). In some embodiments, the GITR agonist is an oligomer of SEQ ID NO:4, in which each monomer comprising the sequence set forth in SEQ ID NO:4 is linked via a linker sequence. In an exemplary embodiment, the linker is GSGSGSGS (SEQ ID NO:5) It is. As described herein, SEQ ID NO:1 comprises an oligomer of SEQ ID NO:4, where each monomer of SEQ ID NO:4 is linked via a linker having the sequence set forth in SEQ ID NO:5.
[0177] In another embodiment, the peptide agonist of GITR comprises, consists of, or consists essentially of a peptide having the sequence set forth in SEQ ID NO:2, or a mutant or functional equivalent thereof.
[0178] TGGRNSIRYSELAPLFDTTRVYLVDNKSTDVASLNYQNDHSNFLTTVIQNNDYSPGEASTQTINLDDRSHWGGDLKTILHTNMPNVNEFMFTNKFKARVMVSRSLTKDKQVELKYEWVEFTLPEGNYSETMTIDLMNNAIVEHYL KVGRQNGVLESDIGVKFDTRNFRLGFDPVTGLVMPGVYTNEAFHPDIILLPGCGVDFTHSRLSNLLGIRKRQPFQEGFRITYDDLEGGNIPALLDVDAYQASLKDDTEQGGDGAGGGNNSGSGAEENSNAAAAAMQPVEDMNDHAI NGS TFATRAEEKRAEAEAEAAAEAAAPAAQPEVEKPQKKPVIKPLTEDSKKRSYNLISNDSTFTQYRSWYLAYNYGDPQTGIRSWTLLCTPDVTCGSEQVYWSLPDMMQDPVTFRSTSQISNFPVVGAELLPVHSKSFYNDQAVYSQLIRQFTSLTHVFNRFPENQILARPPAPTITTVSENVPALTDHGTLPLRNSIGGVQRVTITDARRRTCPYVYKALGIVSPRVLSSRT (GSGSGSGS)nGAMASQLETAKEPCMAKFGPLPSKWQMASSEPPCVNKVSDWKLEILQNGLYLIYGQVAPNANYNDVAPFEVRLYKNKDMIQTLTNKSKIQNVGGTYELHVGDTIDLIFNSEHQVLKNNTYWGIILLANPQFISGSHHHHHH (SEQ ID NO: 2)
[0179] In the formula, the underlined NGS sequences are glycosylation sites and n=1-4.
[0180] Further provided herein are compositions comprising GITR agonists. In one embodiment, the composition comprises a peptide set forth in SEQ ID NO: 1. In another embodiment, the composition comprises a peptide set forth in SEQ ID NO: 2. When administered therapeutically, a peptide agonist of GITR is a composition comprising a peptide having the sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2, further comprising a pharma- ceutically acceptable solution or carrier.
[0181] Further Non-Limiting Embodiments of the Invention
[0182] In some embodiments, a peptide comprising, consisting of, or consisting essentially of the sequence set forth in SEQ ID NO:1 or SEQ ID NO:2, or an analog, pharmaceutical equivalent and / or peptidomimetic thereof, is a modified peptide. A "modified peptide" can include lactam bridges, head-to-tail cyclization, incorporation of non-natural amino acids into the peptides of the invention, including synthetic non-natural amino acids, substituted amino acids, or incorporation of one or more D-amino acids into the peptide (or other components of the composition, excluding protease recognition sequences), which may be desirable in certain circumstances. D-amino acid-containing peptides exhibit increased stability in vitro or in vivo compared to L-amino acid-containing formulations. Thus, constructing peptides incorporating D-amino acids may be particularly useful when greater in vivo or intracellular stability is desired or required. More specifically, D-peptides are resistant to endogenous peptidases and proteases, thereby providing better oral transepithelial and transdermal delivery of linked drugs and conjugates, improved bioavailability of membrane-permanent complexes (see below for further discussion), and extended intravascular and interstitial life spans, where such properties are desired. The use of D-isomer peptides may also enhance transdermal and oral transepithelial delivery of linked drugs and other cargo molecules. Furthermore, D-peptides cannot be efficiently processed for major histocompatibility complex class II-restricted presentation to helper T cells, and are therefore less likely to induce humoral immune responses in the whole organism. Thus, peptide conjugates may be constructed using, for example, D-isomerization of cell-penetrating peptide sequences, L-isomerization of cleavage sites, and D-isomerization of therapeutic peptides. Thus, in some embodiments, the disclosed peptides comprise L and D amino acids, and include no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 D amino acids. In certain embodiments, the peptide comprises more than 10 D-amino acids, and in certain embodiments, all of the amino acids of the peptide are D-amino acids.
[0183] In some embodiments, a peptide comprising, consisting of, or consisting essentially of the sequence shown in SEQ ID NO:1 or SEQ ID NO:2, or an analog, pharmaceutical equivalent, and / or peptidomimetic thereof, is a retro-inverso peptide of said peptide or its analog, pharmaceutical equivalent, and / or peptidomimetic. A "retro-inverso peptide" refers to a peptide having a reversal of the direction of the peptide bond at at least one position, i.e., a reversal of the amino and carboxy termini relative to the amino acid side chains. Thus, a retro-inverso analog reverses the termini and direction of the peptide bonds while largely maintaining the topology of the side chains as in the native peptide sequence. A retro-inverso peptide can contain L- or D-amino acids, or a mixture of L- and D-amino acids, where all amino acids are D-isomers. A partial retro-inverso peptide analog is a polypeptide in which only a portion of the sequence is reversed and replaced with enantiomeric amino acid residues. The retro-inverted portion of such analogs has reversed amino and carboxy termini so that the amino acid residues adjacent to the retro-inverted portion are replaced by side chain analogous alpha-substituted geminal diaminomethane and malonate, respectively. The retro-inverso peptide forms of cell penetrating peptides have been found to act as efficiently as the native forms in translocating across membranes. The synthesis of retro-inverso peptide analogs is described in Bonelli, F. et al., Int J Pept Protein Res. 24(6):553-6(1984); Verdini, A and Viscomi, GC, J. Chem. Soc.Perkin Trans.1:697-701(1985); and U.S. Patent No. 6,261,569, which are incorporated herein by reference in their entireties. A process for the solid phase synthesis of partial reverse inverso peptide analogues is described in EP97994-B, which is also incorporated herein by reference in its entirety.
[0184] Other variants of the peptides described herein (peptides that comprise, consist of, or consist essentially of the sequences set forth in SEQ ID NO:1 or SEQ ID NO:2) may contain conservatively substituted sequences, meaning that one or more amino acid residues of the original peptide are replaced by different residues, and the conservatively substituted peptide retains the desired biological activity (i.e., function as an agonist of GITR (e.g., SEQ ID NO:1 or SEQ ID NO:2) that is essentially equivalent to that of the original peptide). Examples of conservative substitutions include substitutions of amino acids that do not change the secondary and / or tertiary structure of the peptide set forth in SEQ ID NO:1 or SEQ ID NO:2, substitutions that do not change the global or local hydrophobicity, substitutions that do not change the global or local charge, substitutions with residues of equivalent side chain size, or substitutions with side chains having similar reactive groups.
[0185] Other examples include substitutions of amino acids that are not evolutionarily conserved in the parent sequences across species. Advantageously, in some embodiments, these conserved amino acids and structures are not altered when generating conservatively substituted sequences.
[0186] A given amino acid may be substituted with a residue having similar physiochemical properties, for example, by substituting one aliphatic residue for another aliphatic residue (e.g., Ile, Val, Leu, or Ala for each other), or by substituting one polar residue for another polar residue (e.g., between Lys and Arg; between Glu and Asp; or between Gln and Asn). Other such conservative substitutions, for example, the substitution of entire regions with similar hydrophobic properties, or the substitution of residues with similar side chain volumes, are well known. Isolated peptides containing conservative amino acid substitutions may be tested to ensure that the desired activity, such as function as an agonist of GITR (e.g., SEQ ID NO: 1 or SEQ ID NO: 2), is retained.
[0187] Amino acids can be classified according to the similarity of the properties of their side chains (ALLehninger, 2nd ed., pp. 73-75, Worth Publishers, New York (1975)): (1) nonpolar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be divided into groups based on common side chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile, Phe, Trp; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln, Ala, Tyr, His, Pro, Gly; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that affect chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe, Pro, His, or hydroxyproline. Non-conservative substitutions involve exchanging a member of one of these classes for another class.
[0188] Particularly preferred conservative substitutions for use in the variants described herein are: Ala to Gly or Ser; Arg to Lys; Asn to Gln or His; Asp to Glu or Asn; Cys to Ser; Gln to Asn; Glu to Asp; Gly to Ala or Pro; His to Asn or Gln; Ile to Leu or Val; Leu to Ile or Val; Lys to Arg, Gln or Glu; Met to Leu, Tyr or Ile; Phe to Met, Leu or Tyrr; Ser to Thr; Thr to Ser; Trp to Tyr or Phe; Tyr to Phe or Trp; and / or Phe to Val, Tyr, Ile or Leu. In general, conservative substitutions involve the exchange of a residue with one of similar physicochemical properties (ie, the replacement of a hydrophobic residue with another hydrophobic amino acid).
[0189] Any cysteine residue not involved in maintaining the proper conformation of the isolated peptides as described herein also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) can be added to the isolated peptide, as described herein, to improve its stability or to facilitate multimerization.
[0190] As used herein, a "functional fragment" is a fragment or segment of a peptide that contains at least 3, at least 4, or at least 5 amino acids and can function as an agonist of GITR (e.g., SEQ ID NO:1 or SEQ ID NO:2). A functional fragment can include conservative substitutions of the sequences disclosed herein so long as it preserves the function as an agonist of GITR (e.g., SEQ ID NO:1 or SEQ ID NO:2). This can be tested by detecting an increase in function of at least 30%, at least 40%, or at least 50% of the function of the parent (e.g., original) version of the peptide.
[0191] Peptides can be modified to enhance the stability, bioavailability, and / or delivery of peptides to cells.For example, in some embodiments, isolated peptides as described herein can include at least one peptide bond replacement.A single peptide bond or multiple peptide bonds, such as 2 bonds, 3 bonds, 4 bonds, 5 bonds, or 6 or more bonds, or all peptide bonds can be replaced.An isolated peptide described herein can include one type of peptide bond replacement or multiple types of peptide bond replacement, such as 2 types, 3 types, 4 types, 5 types, or more types of peptide bond replacement. Non-limiting examples of peptide bond replacements include ureas, thioureas, carbamates, sulfonylureas, trifluoroethylamines, ortho-(aminoalkyl)-phenylacetic acids, para-(aminoalkyl)-phenylacetic acids, meta-(aminoalkyl)-phenylacetic acids, thioamides, tetrazoles, boronic esters, olefinic groups, and derivatives thereof. In some embodiments, a peptide described herein (a peptide comprising, consisting of, or consisting essentially of a sequence set forth in SEQ ID NO:1 or SEQ ID NO:2), or a variant, derivative, pharmaceutical equivalent, peptidomimetic, or analog thereof, is conjugated to an agent that increases retention in a subject. Examples of agents that increase retention include, but are not limited to, cellulose, fatty acids, polyethylene glycol (PEG), or combinations thereof.
[0192] In some embodiments, the isolated peptides described herein can include naturally occurring amino acids that are typically found in polypeptides and / or proteins produced by an organism, such as, for example, Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M), Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q), Asp (D), Glu (E), Lys (K), Arg (R), and His (H). In some embodiments, the isolated peptides described herein can include alternative amino acids, non-limiting examples of which are D-amino acids, beta amino acids, homocysteine, phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamic acid, hippuric acid, octahydroindole-2-carboxylic acid, statins, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine (3-mercapto-D-valine), ornithine, citrulline, alpha-methylalanine, para-benzoylphenylalanine, para-amino Phenylalanine, p-fluorophenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine, diaminobutyric acid, 7-hydroxytetrahydroisoquinoline carboxylic acid, naphthylalanine, biphenylalanine, cyclohexylalanine, aminoisobutyric acid, norvaline, norleucine, tert-leucine, tetrahydroisoquinoline carboxylic acid, pipecolic acid, phenylglycine, homophenylalanine, cyclohexylglycine, dehydroleucine, 2,2-diethylglycine, 1-amino-1-cyclopentane carboxylic acid, 1-amino-1-cyclohexane carboxylic acid, aminobenzoic acid, aminonaphthoic acid, gamma-aminobutyric acid, difluorophenylalanine, nipecotic acid, alpha-aminobutyric acid, thienylalanine, t-butylglycine, trifluorovaline; hexafluoroleucine; fluorinated analogues; azide-modified amino acids; alkyne-modified amino acids; cyano-modified amino acids; and derivatives thereof.
[0193] In some embodiments, the isolated peptides can be modified, e.g., molecular moieties can be added to one or more of the amino acids that comprise the peptide. In some embodiments, the isolated peptides described herein can comprise one or more moieties, e.g., one or more moieties per peptide, two or more moieties per peptide, five or more moieties per peptide, ten or more moieties per peptide, or one or more moieties per peptide. In some embodiments, the isolated peptides described herein can include one or more types of modifications and / or moieties, e.g., one type of modification, two types of modifications, three types of modifications or more types of modifications. Non-limiting examples of modifications and / or moiety additions include PEGylation; glycosylation; HESylation; ELPylation; lipidation; acetylation; amidation; end-capping modification; cyano group; phosphorylation; and cyclization. In some embodiments, end-capping modification can include N-terminal acetylation, N-terminal acylation, and N-terminal formylation. In some embodiments, end-capping modification can include C-terminal amidation, introduction of C-terminal alcohol, aldehyde, ester, and thioester moieties.
[0194] The isolated peptide as described herein can be bound and / or linked to a second functional molecule, peptide and / or polypeptide. In some embodiments, the isolated peptide as described herein is bound to a targeting molecule. In some embodiments, the isolated peptide as described herein is bound to a targeting molecule by expressing the peptide and the targeting molecule as a fusion peptide, optionally with a peptide linker sequence inserted between them. As used herein, a "targeting molecule" can be any molecule (e.g., a peptide, an antibody or fragment thereof, an antigen, a targeted liposome, or a small molecule that can bind to or be bound by a specific cell or tissue type).
[0195] In some embodiments, an isolated peptide as described herein can be a fusion peptide or polypeptide. A fusion polypeptide can include a first domain that includes the amino acid sequence of a peptide described herein (SEQ ID NO:1 or SEQ ID NO:2), a variant, functional fragment, prodrug, or analog thereof as described herein, and an intervening peptide linker domain between at least a second domain of the fusion peptide. The first peptide domain can be an N-terminal domain or a C-terminal domain or an internal sequence in the case where a partner domain is formed after fragment complementation of the constituent parts. Methods for synthesizing or producing fusion proteins are well known to those skilled in the art. The term "fusion protein" as used herein refers to a recombinant protein of two or more proteins. Fusion proteins can be produced, for example, by linking a nucleic acid sequence encoding one protein to a nucleic acid encoding another protein so that they constitute a single open reading frame that can be translated in a cell into a single polypeptide carrying all the intended proteins. The order of the protein sequences can be varied. Fusion proteins can include epitope tags or half-life extenders. Epitope tags include biotin, FLAG tag, c-myc, hemagglutinin, His6, digoxigenin, FITC, Cy3, Cy5, green fluorescent protein, V5 epitope tag, GST, β-galactosidase, AU1, AU5, and avidin. Half-life extenders include Fc domain and serum albumin.
[0196] In some embodiments, the isolated peptides described herein (e.g., peptides having a sequence shown in SEQ ID NO:1 or SEQ ID NO:2) may be pharmaceutically acceptable prodrugs. As used herein, "prodrug" refers to a compound that can be converted into a therapeutic agent through some chemical or physiological process (e.g., enzymatic process and metabolic hydrolysis). Thus, the term "prodrug" also refers to a precursor of a biologically active compound that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject, i.e., an ester, but is converted to an active compound in vivo, e.g., hydrolyzed to a free carboxylic acid or a free hydroxyl. Prodrug compounds often offer advantages of solubility, tissue compatibility, or delayed release in an organism. The term "prodrug" is also meant to include any covalently bonded carrier that releases an active compound in vivo when administered to a subject. Prodrugs of active compounds can be prepared by modifying functional groups present in the active compound such that the modifications are cleaved to the parent active compound, either by routine manipulation or in vivo. Prodrugs include compounds in which a hydroxy, amino or mercapto group is bonded to any group that is cleaved to form a free hydroxy, free amino or free mercapto group, respectively, when the prodrug of the active compound is administered to a subject. Examples of prodrugs include, but are not limited to, acetate salts of alcohols or acetamides, formate and benzoate derivatives, formamide and benzamide derivatives of amine functional groups in the active compounds, and the like. See Harper, "Drug Latentiation" in Jucker, ed. Progress in Drug Research 4:221-294 (1962); Morozowich et al, "Application of Physical Organic Principles to Prodrug Design" in E. B. Roche ed. Design of Biopharmaceutical Properties through Prodrugs and Analogs, APHA Acad. Pharm. Sci. 40 (1977); Bioreversible Carriers in Drug in Drug Design, Theory and Application, E. B. Roche, ed., APHA Acad. Pharm. Sci. (1987); Design of Prodrugs, H. Bundgaard, Elsevier (1985); Wang et al. "Prodrug approaches to the improved delivery of peptide drug" in Curr. Pharm. Design. 5(4):265-287 (1999); Pauletti et al. (1997) Improvement in peptide bioavailability: Peptidomimetics and Prodrug Strategies, Adv. Drug. Delivery Rev. 27:235-256; Mizen et al. (1998) "The Use of Esters as Prodrugs for Oral Delivery of (3-Lactam antibiotics," Pharm. Biotech. ll,:345-365; Gaignault et al. (1996) "Designing Prodrugs and Bioprecursors I. Carrier Prodrugs," Pract. Med. Chem.671-696; Asgharnejad, "Improving Oral Drug Transport", in Transport Processes in Pharmaceutical Systems, G. L. Amidon, P. I. Lee and E. M. Topp, Eds., Marcell Dekker, p. 185-218 (2000); Balant et al., "Prodrugs for the improvement of drug absorption via different routes of administration", Eur. J. Drug Metab. Pharmacokinet., 15(2): 143-53 (1990); Balimane and Sinko, "Involvement of multiple transporters in the oral absorption of nucleoside analogues", Adv. Drug Delivery Rev., 39(1-3): 183-209 (1999); Browne, "Fosphenytoin (Cerebyx)", Clin. Neuropharmacol. 20(1): 1-12 (1997); Bundgaard, "Bioreversible derivatization of drugs- principle and applicability to improve the therapeutic effects of drugs", Arch. Pharm. Chemi 86(1): 1-39 (1979); Bundgaard H. "Improved drug delivery by the prodrug approach", Controlled Drug Delivery 17: 179-96 (1987); Bundgaard H. "Prodrugs as a means to improve the delivery of peptide drugs",Arfv. Drug Delivery Rev. 8(1): 1-38 (1992); Fleisher et al."Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Arfv. Drug Delivery Rev. 19(2): 115-130 (1996); Fleisher et al. "Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting", Methods Enzymol. 112 (Drug Enzyme Targeting, Pt. A): 360-81, (1985); Farquhar D, et al., "Biologically Reversible Phosphate-Protective Groups", Pharm. Sci., 72(3): 324-325 (1983); Freeman S, et al., "Bioreversible Protection for the Phospho Group: Chemical Stability and Bioactivation of Di(4-acetoxy-benzyl) Methylphosphonate with Carboxyesterase," Chem. Soc., Chem. Commun., 875-877 (1991); Friis and Bundgaard, "Prodrugs of phosphates and phosphonates: Novel lipophilic alphaacyloxyalkyl ester derivatives of phosphate- or phosphonate containing drugs masking the negative charges of these groups", Eur. J. Pharm. Sci. 4: 49-59 (1996); Gangwar et al., "Pro-drug, molecular structure and percutaneous delivery", Des. Biopharm. Prop.Prodrugs Analogs, [Symp.] Meeting Date 1976, 409-21. (1977); Nathwani and Wood, "Penicillins: a current review of their clinical pharmacology and therapeutic use", Drugs 45(6): 866-94 (1993); Sinhababu and Thakker, "Prodrugs of anticancer agents", Adv. Drug Delivery Rev. 19(2): 241-273 (1996); Stella et al., "Prodrugs. Do they have advantages in clinical practice?", Drugs 29(5): 455-73 (1985); Tan et al. "Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics", Adv. Drug Delivery Rev. 39(1-3): 117-151 (1999); Taylor, "Improved passive oral drug delivery via prodrugs", Adv. Drug Delivery Rev., 19(2): 131-148 (1996); Valentino and Borchardt, "Prodrug strategies to enhance the intestinal absorption of peptides", Drug Discovery Today 2(4): 148-155 (1997); Wiebe and Knaus, "Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection", Adv.Drug Delivery Rev.: 39(1-3):63-80 (1999); Waller et al., "Prodrugs", Br. J. Clin. Pharmac. 28: 497-507 (1989), which are incorporated by reference herein in their entireties.
[0197] In some embodiments, the isolated peptides described herein may be in a pharma- ceutically acceptable solvate. The term "solvate" refers to an isolated peptide as described herein in the solid state, where molecules of a suitable solvent are incorporated into the crystal lattice. Suitable solvents for therapeutic administration are physiologically acceptable at the administered dosage. Examples of suitable solvents for therapeutic administration are ethanol and water. When water is the solvent, the solvate is called a hydrate. In general, solvates are formed by dissolving the compound in a suitable solvent and isolating the solvate by cooling or using an antisolvent. The solvate is typically dried or azeotroped under ambient conditions.
[0198] In some embodiments, the isolated peptides described herein may be non-crystalline, i.e., in an amorphous solid form.
[0199] In one embodiment, described herein is a vector comprising a nucleic acid encoding a peptide described herein. The term "vector" as used herein refers to a nucleic acid construct designed for delivery to a host cell or transfer between different host cells, and as used herein, a vector can be viral or non-viral. The term "vector" encompasses any genetic element that is capable of replicating and transferring genetic sequences to a cell when associated with the appropriate control elements. Vectors can include, but are not limited to, cloning vectors, expression vectors, plasmids, phages, transposons, cosmids, chromosomes, viruses, virions, and the like. Many vectors are available that are useful for introducing foreign genes into target mammalian cells. The vectors can be episomal, e.g., plasmids, virus-derived vectors, e.g., cytomegalovirus, adenovirus, and the like, or can integrate into the target cell genome via homologous recombination or random integration, e.g., retrovirus-derived vectors, e.g., MMLV, HIV-1, ALV, and the like. Many viral vectors are known in the art and can be used as carriers of nucleic acid regulatory compounds into cells. For example, a construct containing a nucleic acid encoding a polypeptide can be incorporated and packaged into a non-replicating defective viral genome, such as adenovirus, adeno-associated virus (AAV), or herpes simplex virus (HSV), or others, including retrovirus and lentivirus vectors, for infection or transduction into cells. Alternatively, the construct can be incorporated into a vector capable of episomal replication (e.g., EPV and EBV vectors). The nucleic acid incorporated into the vector can be operably linked to an expression control sequence such that the expression control sequence controls and regulates the transcription and translation of the polynucleotide sequence.
[0200] As used herein, the term "expression vector" refers to a vector that directs the expression of an RNA or polypeptide from a sequence linked to a transcription control sequence on the vector. The sequence to be expressed is often, but not necessarily, heterologous to the cell. An expression vector can contain additional elements, for example, an expression vector can have two replication systems, thus allowing it to be maintained in two organisms, for example, a human cell for expression, and a prokaryotic host for cloning and amplification.
[0201] The term "transfection," as used herein for methods such as chemical methods, is used herein as a method for introducing exogenous nucleic acid, such as a nucleic acid sequence encoding a peptide as described herein, into a cell. As used herein, the term transfection does not encompass viral-based methods of introducing exogenous nucleic acid into a cell. Transfection methods include physical treatments (electroporation, nanoparticles, magnetofection) and chemical-based transfection methods. Chemical-based transfection methods include, but are not limited to, those using cyclodextrins, polymers, liposomes, nanoparticles, cationic lipids or mixtures thereof (e.g., DOPA, lipofectamine, and UptiFectin), and cationic polymers such as DEAE-dextran or polyethyleneimine.
[0202] As used herein, the term "viral vector" refers to a nucleic acid vector construct that contains at least one element of viral origin and has the ability to be packaged into a viral vector particle. A viral vector can contain a nucleic acid encoding a peptide described herein in place of a non-essential viral gene. The vector and / or particle can be utilized to introduce any nucleic acid into a cell, either in vitro or in vivo. Many forms of viral vectors are known in the art. When used in reference to a viral vector, the term "replication incompetent" refers to the inability of the viral vector to further replicate and package its genome. For example, when a subject's cells are infected with a replication incompetent recombinant adeno-associated virus (rAAV) virion, the heterologous (also known as transgene) gene is expressed in the patient's cells, but the rAAV is replication incompetent (e.g., lacking accessory genes that code for essential proteins for packaging the virus), and viral particles cannot be formed in the following. As used herein, the term "transduction" refers to the use of a viral particle or virus to introduce exogenous nucleic acid into a cell.
[0203] Retroviruses (e.g., lentiviruses) provide a convenient platform for delivery of nucleic acid sequences encoding factors of interest. A selected nucleic acid sequence can be inserted into a vector and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to cells, for example, in vitro or ex vivo. Retroviral systems are well known in the art and are described, for example, in US Pat. No. 5,219,740; Kurth and Bannert (2010) "Retroviruses: Molecular Biology, Genomics and Pathogenesis" Calster Academic Press (ISBN:978-1-90455-55-4); and Hu and Pathak Pharmacological Reviews 2000 52:493-512; which are incorporated herein by reference in their entirety.
[0204] In some embodiments, the nucleotide sequence of interest is inserted into an adenovirus-based expression vector.Unlike retroviruses that are integrated into the host genome, adenoviruses persist extrachromosomally, thus minimizing the risk associated with insertional mutagenesis (Haj-Ahmad and Graham (1986) J. Virol. 57:267-74; Bett et al. (1993) J. Virol. 67:5911-21; Mittereder et al. (1994) Human Gene Therapy 5:717-29; Seth et al. (1994) J. Virol. 68:933-40; Barr et al. (1994) Gene Therapy 1:51-58; Berkner, KL (1988) BioTechniques 6:616-29; and Rich et al. (1993) Human Gene Therapy 4:461-76). Adenovirus vectors have several advantages in gene therapy: they infect a wide variety of cells, have a broad host range, show high efficiency of infection, direct expression of heterologous sequences at high levels, and achieve long-term expression of those sequences in vivo. The virus is fully infectious as a cell-free virion, so injection of producer cell lines is unnecessary. With regard to safety, adenoviruses are not associated with serious human pathology, and recombinant vectors derived from the virus can be made replication-defective by deletion of the early region 1 ("E1") of the viral genome. Adenoviruses can also be produced in large quantities with relative ease. For all these reasons, vectors derived from human adenoviruses, with at least the E1 region deleted and replaced with the gene of interest, have been widely used in gene therapy experiments in the preclinical and clinical stages. Adenoviral vectors for use with the compositions and methods described herein can be derived from any of the various adenovirus serotypes, including, but not limited to, any of the more than 40 serotype strains of adenovirus, such as serotypes 2, 5, 12, 40, and 41. The adenoviral vectors used in the methods described herein are generally replication-deficient and contain a sequence of interest under the control of an appropriate promoter. For example, U.S. Patent No. 6,048,551 describes a replication-deficient adenovirus vector containing a human gene under the control of a Rous sarcoma virus (RSV) promoter, and is incorporated herein by reference in its entirety. Other recombinant adenoviruses containing different promoter systems of various serotypes can be made by those skilled in the art. See, for example, U.S. Patent No. 6,306,652, which is incorporated herein by reference in its entirety. Other useful adenovirus-based vectors for delivery of nucleic acid sequences include "minimal" adenovirus vectors, as described in U.S. Patent No. 6,306,652, which retain at least a portion of the viral genome required for encapsidation (encapsidation signal), as well as at least one copy of at least one functional portion or derivative of the ITR; and "gattleless" (helper-dependent) adenoviruses, which are adenoviruses from which most of the viral genome has been removed and which essentially do not produce viral proteins. Such vectors may allow sustained gene expression for up to a year after a single administration (Wu et al. (2001) Anesthes. 94:1119-32; Parks (2000) Clin. Genet. 58:1-11; Tsai et al. (2000) Curr. Opin. Mol. Ther. 2:515-23).
[0205] In some embodiments, the nucleotide sequence encoding the peptide described herein is inserted into an adeno-associated virus-based expression vector. AAV is a parvovirus belonging to the Dependovirus genus and has several features not found in other viruses. AAV can infect a wide range of host cells, including non-dividing cells. AAV can infect cells of different species. AAV is not associated with any human or animal disease and does not appear to alter the biological properties of the host cell upon integration. In fact, it is estimated that 80-85% of the human population is exposed to this virus. Finally, AAV is stable over a wide range of physical and chemical conditions, facilitating production, storage and transportation. AAV is a helper-dependent virus; i.e., it requires co-infection with a helper virus (e.g., adenovirus, herpesvirus or vaccinia) to form AAV virions in the wild. In the absence of co-infection with a helper virus, AAV establishes a latent state in which the viral genome is inserted into the host cell chromosome, but no infectious virions are produced. Subsequent infection with a helper virus rescues the integrated genome, allowing it to replicate and be packaged into infectious AAV virions. AAV can infect cells of different species, but the helper virus must be of the same species as the host cell. Thus, for example, human AAV replicates in canine cells co-infected with a canine adenovirus. Adeno-associated viruses (AAV) have been successfully used in gene therapy. AAV has been engineered to deliver a gene of interest by deleting the internal non-repetitive portion of the AAV genome (i.e., the rep and cap genes) and inserting a heterologous sequence (in this case, a sequence encoding an agent) between the ITRs. The heterologous sequence is typically operably linked to a heterologous promoter (constitutive, cell-specific, or inducible) capable of driving expression in the patient's target cells under appropriate conditions. Recombinant AAV virions containing a nucleic acid sequence encoding an agent of interest can be produced using a variety of art-recognized techniques, as described in U.S. patents. U.S. Patent Nos. 5,139,941; 5,622,856; 5,622,856; 5,139,941; 6,001,650; and 6,004,797, the contents of each of which are incorporated by reference in their entirety. The vectors and cell lines necessary for preparing helper virus-free rAAV stocks are commercially available as the AAV Helper-Free System (catalog number 240071) (Agilent Technologies, Santa Clara, Calif.).
[0206] Additional viral vectors useful for delivering nucleic acid molecules encoding the peptides described herein include those derived from the pox family of viruses, including vaccinia virus and avipox virus. Alternatively, avipox viruses, such as fowlpox virus and canarypox virus, can be used to carry genes. The use of avipox vectors in cells of human and other mammalian species has safety advantages, since members of the avipox genus can only productively replicate in susceptible avian species. Methods for producing recombinant avipox viruses are known in the art and use genetic recombination (see, for example, WO 91 / 12882; WO 89 / 03429; and WO 92 / 03545).
[0207] Molecular conjugate vectors such as adenovirus chimeric vectors can also be used for delivery of sequences encoding peptides as described herein (Michael et al. (1993) J. Biol. Chem. 268:6866-69 and Wagner et al. (1992) Proc. Natl. Acad. Sci. USA 89:6099-6103). Members of the alphavirus genus, such as Sindbis and Semliki Forest viruses, can also be used as viral vectors to deliver nucleic acid sequences (see, e.g., Dubensky et al. (1996) J. Virol. 70:508-19; WO 95 / 07995; WO 96 / 17072).
[0208] In some embodiments, the vector further comprises a signal peptide operably linked to the peptide. A signal peptide is a peptide sequence located at the terminus (usually the N-terminus) that provides for passage of a protein to or through a membrane. Different signal peptides may be useful in different applications. For example, for a cell line for the production of isolated peptides as described herein, a secretory signal peptide may allow for increased yield and ease of purification. As a further example, for a cell that produces a peptide as described herein and is administered to a subject for therapeutic purposes, multiple signal peptides, for example, a peptide signaling for secretion from a first cell, a peptide signaling for internalization by a second cell, and a final peptide signaling for nuclear localization, may increase the amount of peptide that reaches the target environment. As a further example, for example, for gene therapy applications, a peptide signaling for nuclear localization may increase the amount of peptide that reaches the target environment. Signal peptides are known in the art. Non-limiting examples of nuclear localization signal (NLS) peptides for use in mammalian cells include the SV40 large T antigen NLS; the nucleoplasmin NLS; the KK / RXK / R consensus NLS. Additional signal peptides are known in the art, and the choice of signal peptide can be influenced by the cell type, growth conditions, and the desired destination of the peptide.
[0209] In one embodiment, described herein is a cell expressing a vector comprising a nucleic acid encoding a peptide described herein. In some embodiments, the cell expressing a vector described herein is a cell suitable for producing a polypeptide. The cell suitable for producing a polypeptide can be a prokaryotic or eukaryotic cell, such as a bacteria, a virus, a yeast, a fungus, a mammalian cell, an insect cell, a plant cell, etc. As a non-limiting example, cells for the production of proteins are commercially available (e.g., bacterial cells (BL21-derived cells-Cat. No. 60401-1, Lucigen; Middleton, WI) and mammalian cells (293F cells-Cat. No. 11625-019, Invitrogen; Grand Island, NY)).
[0210] Recombinant molecules (e.g., vectors as described herein) can be introduced into cells via transformation, particularly transduction, conjugation, lipofection, protoplast fusion, mobilization, particle bombardment, electroporation (Neumann et al., "Gene Transfer into Mouse Lyoma Cells by Electroporation in High Electric Fields," EMBO J. 1(7):841-845 (1982); Wong et al., "Electric Field Mediated Gene Transfer," Biochem Biophys Res Commun 107(2):584-587 (1982); Potter et al., "Enhancer-dependent Expression of Human Kappa Immunoglobulin Genes Introduced into Mouse pre-B Lymphocytes by Electroporation," Proc. Natl. Acad. Sci. USA 81(22):7161-7165 (1984), the entire contents of which are incorporated herein by reference), polyethylene glycol-mediated DNA uptake (Joseph Sambrook & David W. Russell, Molecular Cloning: A Laboratory Manual cp. 16(2d ed. 1989), the entire contents of which are incorporated herein by reference), or fusion of protoplasts with other solid tissues (e.g., minicells, cells, lysosomes, or other fusogenic lipid surface tissues containing the chimeric gene) (Fraley et al., "Liposome-mediated Delivery of Tobacco Mosaic Virus RNA into Tobacco Protoplasts: A Sensitive Assay for Monitoring Liposome-protoplast Interactions", Proc. Natl. Acad. Sci. USA, 79(6):1859-1863(1982), the entire contents of which are incorporated herein by reference). The host cells are then cultured in an appropriate medium under conditions suitable for expression of the protein or polypeptide of interest. After culturing, the cells are disrupted by physical or chemical means and the protein or polypeptide is purified from the resulting crude extract. Alternatively, the culturing may include conditions under which the protein or polypeptide is secreted into the growth medium of the recombinant host cells and the protein or polypeptide is isolated from the growth medium. Alternative methods may be used if appropriate.
[0211] The peptides may also be coupled to an adjuvant. The term "adjuvant" refers to a compound or mixture that enhances the immune response and / or promotes proper absorption rates after inoculation, and as used herein includes any uptake enhancer. Non-limiting examples of adjuvants include chemokines (e.g., defensins, HCC-1, HCC4, MCP-1, MCP-3, MCP-4, MIP-1α, MIP-1β, MIP-1δ, MIP-3α, MIP-2, RANTES); other ligands for chemokine receptors (e.g., CCR1, CCR-2, CCR-5, CCR-6, CXCR-1); cytokines (e.g., IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17(AF), IL-18; IFNα, IFN-γ; TNF-α; GM-CSF; TGF-β; FLT-3 ligand; CD40 ligand; other ligands for these cytokines; Th1 cytokines, including but not limited to IFNγ, IL-2, IL-12, IL-18 and TNF; Th2 cytokines, including but not limited to IL-4, IL-5, IL-10 and IL-13; and Th17 cytokines, including but not limited to IL-17 (A-F), IL-23, TGF-β and IL-6; immunostimulatory CpG motifs in bacterial DNA or oligonucleotides; derivatives of lipopolysaccharides such as monophosphoryl lipid A (MPL); murabutyridipeptide (MDP) and its derivatives (e.g., murabutide, threonyl-MDP, muramyl tripeptide, N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP); N-acetylnormuramyl-L-alanyl-D-isoglutamine (CGP 11637, cited for nor-MDP); N-Acetylmuraminyl-L-alanyl-D-isoglutamyl-L-alani-ne-2-(1'-2'-dipalmitoyl-sn-glycero-3 hydroxyphosphoryloxy)-ethylamine (CGP 19835A, see MTP-PE); MF59 International Publication No. WO 90 / 14837; Poly[di(carboxylatophenoxy)phosphazene] (PCPP polymer; Virus Research Institute, USA); RIBI (GSK); Contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene / Tween 80 emulsion;OM-174 (glucosamine disaccharides related to lipid A; OM Pharma SA, Meyrin, Switzerland); heat shock proteins and derivatives thereof; Leishmania analogs of e1F4a and derivatives thereof; bacterial ADP-ribosylating exotoxins and derivatives thereof (e.g. genetic mutants, A and / or B subunit containing fragments, chemical toxoid mutants; chemical conjugates or recombinants comprising bacterial ADP-ribosylating exotoxins or derivatives thereof; C3D tandem arrays; lipid A and derivatives thereof (e.g. monophosphoryl or diphosphoryl lipid A, lipid A analogs, AGP, AS02, AS04, DC-Chol, Detox, OM-174); ISCOMS and saponins (e.g. Quil A, QS-21, Stimulon® (Cambridge Bioscience, Worcester, MA); squalene; superantigens; or salts (e.g. aluminum hydroxide or calcium phosphate, calcium phosphate). For other useful adjuvants, see also; ohria et al. Biotherapy, 7:261-269, 1994; Richards et al., in Vaccine Design, Eds. Powell et al., Plenum Press, 1995; and Pashine et al., Nature Medicine, 11:S63-S68, 4 / 2005). Further examples of adjuvants may include the RIBI adjuvant system (Ribi Inc., Hamilton, MT), alum, mineral gels such as aluminum hydroxide gel, oil-in-water emulsions, water-in-oil emulsions such as Freund's complete and incomplete adjuvants, block copolymers (CytRx, Atlanta GA), QS-21 (Cambridge Biotech Inc., Cambridge MA), and SAF-M (Chiron, Emeryville CA), AMPHIGEN® adjuvant, saponin, Quil A or other saponin fractions, monophosphoryl lipid A, and Avridine lipid-amine adjuvants, as well as METASTIM®. Other suitable adjuvants include, for example, lysolecithin, pluronics. (登録商標) Surface active substances such as polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanin, dinitrophenol, and the like may be included.
[0212] In some embodiments, cells can be genetically engineered to express the peptides described herein, and the genetically engineered cells can be used for cell therapy. In some embodiments, cell therapy is also considered as ex vivo therapy. Examples of cells that can be used include, but are not limited to, dendritic cells, T lymphocytes (T cells), naive T cells (TN), memory T cells (e.g., central memory T cells (TCM), effector memory cells (TEM)), natural killer cells, hematopoietic stem cells, and / or pluripotent embryonic / induced stem cells that can give rise to therapeutically relevant progeny. In one embodiment, the genetically engineered cells are autologous cells. By way of example, the individual T cells of the present invention can be CD4+ / CD8-, CD4- / CD8+, CD4- / CD8-, or CD4+ / CD8+. The T cells can be a mixed population of CD4+ / CD8- and CD4- / CD8+ cells, or a population of single clones. CD4+ T cells produce IL-2, IFN-γ, TNFα and other T cell effector cytokines when co-cultured in vitro with cells expressing the peptide (e.g., CD20+ and / or CD19+ tumor cells). CD8+ T cells can lyse antigen-specific target cells when co-cultured in vitro with target cells. In some embodiments, the T cells express CD45RA + CD62L + Naïve cells, CD45RO + CD62L + Central memory cells, CD62 -The immune system may be any one or more of: immune cells, effector memory cells, or a combination thereof (Berger et al., Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 2009 21(2)224-232).
[0213] In some embodiments, the tolerized antigen presenting cells can be used in cell therapy. Examples include B cells, dendritic cells, macrophages, etc. The cells can be of any origin, including human. The cells can be tolerized using the peptides described herein. In some embodiments, the cells are tolerized in the presence of cytokines.
[0214] In some embodiments, cells producing the peptides described herein can be administered to a subject, for example, to treat, inhibit, reduce the severity and / or progression of cancer (SEQ ID NO:1 and / or SEQ ID NO:2).
[0215] In some embodiments, nanoparticles containing the peptides described herein can be administered to a subject. In some embodiments, nanoparticles for use with the peptides described herein are described in Levine et al.;Polymersomes: A new multi-functional tool for cancer diagnosis and therapy. Methods 2008 Vol 46 pg 25-32 or as described in S Jain, et al., Gold nanoparticles as novel agents for cancer therapy. Br J Radiol. 2012 Feb; 85(1010): 101-113., all of which are incorporated herein by reference.
[0216] In some embodiments, cells expressing vectors encoding peptides described herein can be cells of a patient that has been genetically engineered to treat, inhibit, reduce the severity and / or slow the progression of diabetes, such as type 2 diabetes. Vectors for gene therapy can include viral or non-viral vectors, as described elsewhere herein.
[0217] Pharmaceutical Compositions
[0218] In various embodiments, the present invention provides a pharmaceutical composition comprising a composition having one or more compounds of the present invention; and a pharma- ceutically acceptable carrier.In one embodiment, the compound is one or more agonists of GITR (e.g., a peptide having a sequence shown in SEQ ID NO:1, SEQ ID NO:2, or a variant, derivative or functional equivalent thereof, or a compound of formula I).In another embodiment, the compound is one or more antagonists of GITR (e.g., a compound of formula II).
[0219] For administration to a patient, the compositions described herein may be provided as pharma- ceutically acceptable compositions that contain peptides and / or compounds capable of functioning as agonists or antagonists of GITR as described herein, formulated together with one or more pharma- ceutically acceptable carriers (excipients) and / or diluents. As described in detail below, the pharmaceutical compositions of the present invention may be administered (1) orally, e.g., by drench (aqueous or non-aqueous solution or suspension), tube feeding, sweetened tablet, dragee, capsule, pill, tablet (e.g., buccal, sublingual, and targeted for systemic absorption), bolus (rapid administration), powder, granule, sublingual paste; (2) parenterally, e.g., subcutaneous, intramuscular, intravenous, or epidural administration of a sterile solution or suspension, or sustained release formulation; (3) topically, e.g., by cream, ointment, or sustained release patch or spray applied to the skin; (5) sublingually; (6) ophthalmic; (7) transdermal; (8) transmucosal; or (9) nasally. Additionally, the compounds may be implanted into the patient or injected using a drug delivery system. See, e.g., Urquhart, et al., Ann. Rev. Pharmacol. Toxicol. 24: 199-236 (1984); Lewis, ed. "Controlled Release of Pesticides and Pharmaceuticals" (Plenum Press, New York, 1981); US Pat. No. 3,773,919; and US Pat. No. 35 3,270,960, contents of all of which are herein incorporated by reference. Rev., the entire contents of which are incorporated herein by reference.
[0220] As used herein, the term "pharmacologically acceptable or tolerable" refers to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0221] As used herein, "pharmacologically acceptable or tolerable carrier" refers to a pharma- ceutically acceptable substance, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, magnesium, calcium, or zinc stearate, or stearic acid), or solvent encapsulating material that is involved in carrying or transporting the compound of interest from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other components of the formulation and not injurious to the patient. Some examples of materials which serve as pharma- ceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, microcrystalline cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricants, such as magnesium stearate, sodium lauryl sulfate, and talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; and (10) propylene glycol. (11) glycols such as glycerol, (12) polyols such as sorbitol, mannitol and polyethylene glycol (PEG), (13) esters such as ethyl oleate and ethyl laurate, (14) buffers such as magnesium hydroxide and aluminum hydroxide, (15) alginic acid, (16) pyrogen-free water, (17) isotonic saline, (18) Ringer's solution, (19) ethyl alcohol, (20) pH buffer solutions, (21) polyesters, polycarbonates and / or polyanhydrides, (22) bulking agents such as polypeptides and amino acids, (23) serum components such as serum albumin, HDL and LDL, (24) C-terminal amino acids such as ethanol, (25) glycerides such as glycerides, glycerols ... 2 -C 12 Alcohol, and (24) other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweetening agents, flavoring agents, perfumes, preservatives and antioxidants may also be present in the formulation. The terms "excipient", "carrier", "pharmaceutical acceptable carrier" and the like are used interchangeably herein.
[0222] The pharmaceutical composition according to the present invention can also be prepared in an emulsion or syrup, encapsulated or tableted for oral administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, alcohol and water. Solid carriers include starch, lactose, calcium sulfate, dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. Carriers also include sustained release materials such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
[0223] The pharmaceutical composition is prepared according to conventional techniques of pharmacy, including dry grinding, mixing, and blending for powder form; grinding, mixing, granulation, and compression as necessary for tablet form; or grinding, mixing, and filling for hard gelatin capsule form.When using liquid carrier, the preparation is made into the form of syrup, elixir, emulsion or aqueous or non-aqueous suspension.Such liquid preparation can be directly administered orally or filled into soft gelatin capsule.
[0224] Before administration to a patient, a formulation may be added to the composition. A liquid formulation may be preferred. For example, such a formulation may include oils, polymers, vitamins, carbohydrates, amino acids, salts, buffers, albumin, surfactants, bulking agents, or combinations thereof.
[0225] The carbohydrate formulation includes a sugar or sugar alcohol, such as a monosaccharide, disaccharide, or polysaccharide, or a water-soluble glucan. The sugar or glucan can include fructose, dextrose, lactose, glucose, mannose, sorbose, xylose, maltose, sucrose, dextran, pullulan, dextrin, alpha and beta cyclodextrin, soluble starch, hydroxyethyl starch, and carboxymethyl cellulose, or mixtures thereof. "Sugar alcohol" is defined as a C4-C8 hydrocarbon having an -OH group, and includes galactitol, inositol, mannitol, xylitol, sorbitol, glycerol, and arabitol. These sugars or sugar alcohols may be used alone or in combination. There is no fixed limit to the amount used, so long as the sugar or sugar alcohol is soluble in the aqueous preparation. In one embodiment, the sugar or sugar alcohol concentration is 1.0 w / v% to 7.0 w / v%, more preferably 2.0 to 6.0 w / v%.
[0226] The amino acid formulation includes the levorotary (L) forms of carnitine, arginine, and betaine, although other amino acids may be added.
[0227] The polymer formulation includes polyvinylpyrrolidone (PVP) having an average molecular weight of 2,000 to 3,000, or polyethylene glycol (PEG) having an average molecular weight of 3,000 to 5,000.
[0228] It is also preferred to use a buffer in the composition to minimize pH changes in the solution before lyophilization or after reconstitution. Almost any physiological buffer can be used, including but not limited to citrate, phosphate, succinate, and glutamate buffers or mixtures thereof. In some embodiments, the concentration is 0.01 to 0.3 molar. Surfactants that can be added to the formulation are listed in EP Nos. 270,799 and 268,110.
[0229] Another drug delivery system for increasing circulation half-life is the liposome. Methods for preparing liposomal delivery systems are disclosed below; Gabizon et al., Cancer Research (1982) 42:4734; Cafiso, Biochem Biophys Acta (1981) 649:129; and Szoka, Ann Rev Biophys Eng (1980) 9:467. Other drug delivery systems are known in the art and are described, for example, in Poznansky et al., DRUG DELIVERY SYSTEMS (ed. RL Juliano, Oxford, NY 1980), pp. 253-315; ML Poznansky, Pharm Revs (1984) 36:277.
[0230] After preparing the liquid pharmaceutical composition, it can be lyophilized to prevent degradation and preserve sterility. Methods for lyophilizing liquid compositions are known to those skilled in the art. Just before use, the composition can be reconstituted with a sterile diluent (e.g., Ringer's solution, distilled water, or sterile saline) that may contain additional ingredients. Once reconstituted, the composition is administered to a subject using methods known to those skilled in the art.
[0231] The compositions of the present invention can be sterilized by conventional well-known sterilization techniques. The resulting solution can be packaged for use or can be aseptically filtered and lyophilized, and the lyophilized preparation can be combined with a sterile solution before administration. The compositions can contain pharma- ceutically acceptable auxiliary substances required to approximate physiological conditions, such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, and stabilizers (e.g., 1-20% maltose, etc.).
[0232] As used herein, the phrase "therapeutically effective amount" refers to an amount of a drug, compound, substance, or composition containing same that is effective to produce some desired therapeutic effect in at least a subpopulation of cells in an animal, with a reasonable benefit / risk ratio applicable to medical treatment. Determination of a therapeutically effective amount is well within the capabilities of one of ordinary skill in the art. Generally, a therapeutically effective amount may vary depending on the subject's medical history, age, condition, and the severity and type of medical condition in the subject, as well as administration.
[0233] The amount of compositions containing peptides and / or compounds capable of functioning as agonists or antagonists of GITR as described herein that can be combined with carrier materials to produce a single dosage form is generally that amount of drug that produces a therapeutic effect. Generally, out of 100 percent, this amount will range from about 0.01% to 99% of the drug, preferably from about 5% to about 70%, and most preferably from 10% to about 30%.
[0234] Toxicity and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio between LD50 and ED50. Compositions that exhibit large therapeutic indices are preferred.
[0235] As used herein, the term ED refers to effective dose and is used in connection with animal models. The term EC refers to effective concentration and is used in connection with in vitro models.
[0236] Data obtained from cell culture assays and animal studies can be used to formulate a range of dosages for use in humans.The dosage of such compounds is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.Dosages can vary within this range depending on the dosage form used and the route of administration utilized.
[0237] The therapeutically effective dose can be estimated initially from cell culture assays. The dose can be formulated in animal models to achieve a circulating plasma concentration range that includes IC50 (i.e., the concentration of therapeutic agent that achieves half-maximal inhibition of symptoms) as determined in cell culture. Levels in plasma can be measured, for example, by high performance liquid chromatography. The effect of any particular dosage can be monitored by suitable bioassays.
[0238] Dosage can be determined by a physician and can be adjusted, if necessary, to suit the observed effects of the treatment. Generally, the composition is administered such that the agent is administered in a single dosage of 1 μg / kg to 150 mg / kg, 1 μg / kg to 100 mg / kg, 1 μg / kg to 50 mg / kg, 1 μg / kg to 20 mg / kg, 1 μg / kg to 10 mg / kg, 1 μg / kg to 1 mg / kg, 100 μg / kg to 100 mg / kg, 100 μg / kg to 50 mg / kg, 100 μg / kg to 20 mg / kg, 100 μg / kg to 10 mg / kg, 100 μg / kg to 1 mg / kg, 1 mg / kg to 100 mg / kg, 1 mg / kg to 50 mg / kg, 1 mg / kg to 20 mg / kg, 1 mg / kg to 10 mg / kg, 10 mg / kg to 100 mg / kg, 10 mg / kg to 50 mg / kg, or 10 mg / kg to 20 mg / kg / kg. Ranges given herein, for example 1 mg / kg to 10 mg / kg, are understood to include all intermediate ranges such as 1 mg / kg to 2 mg / kg, 1 mg / kg to 3 mg / kg, 1 mg / kg to 4 mg / kg, 1 mg / kg to 5 mg / kg, 1 mg / kg to 6 mg / kg, 1 mg / kg to 7 mg / kg, 1 mg / kg to 8 mg / kg, 1 mg / kg to 9 mg / kg, 2 mg / kg to 10 mg / kg, 3 mg / kg to 10 mg / kg, 4 mg / kg to 10 mg / kg, 5 mg / kg to 10 mg / kg, 6 mg / kg to 10 mg / kg, 7 mg / kg to 10 mg / kg, 8 mg / kg to 10 mg / kg, 9 mg / kg to 10 mg / kg, etc. Furthermore, it should be understood that intermediate ranges above, for example, dose ranges of 1 mg / kg to 10 mg / kg, 2 mg / kg to 8 mg / kg, 3 mg / kg to 7 mg / kg, 4 mg / kg to 6 mg / kg, etc., are also within the scope of the present invention.
[0239] In some embodiments, the composition is administered at a dose such that 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours or more after administration, the agent or a metabolite thereof has an in vivo concentration of less than 500 nM, less than 400 nM, less than 300 nM, less than 250 nM, less than 200 nM, less than 150 nM, less than 100 nM, less than 50 nM, less than 25 nM, less than 20 nM, less than 10 nM, less than 5 nM, less than 1 nM, less than 0.5 nM, less than 0.1 nM, less than 0.05, less than 0.01 nM, less than 0.005 nM, less than 0.001 nM, less than 0.001 nM.
[0240] With regard to duration and frequency of treatment, a skilled clinician will typically monitor the subject to determine when the treatment is providing therapeutic benefit and to determine whether to increase or decrease the dosage, increase or decrease the frequency of administration, discontinue treatment, resume treatment, or make other changes to the treatment regimen. Dosing schedules can vary from once a week to once a day, depending on a number of clinical factors, such as the subject's sensitivity to the polypeptide. The desired dose can be administered daily, or every 3, 4, 5, or 6 days. The desired dose can be administered once or divided into subdoses (e.g., 2-4 subdoses) and administered over a period of time (e.g., at appropriate intervals throughout the day, or on other suitable schedules). Such subdoses can be administered as unit dosage forms. In some embodiments of the aspects described herein, administration is chronic (e.g., one or more doses daily for a period of weeks or months). Examples of dosing regimens are once daily, twice daily, three times daily, or four or more times daily for a period of 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more.
[0241] As used herein, "contacting" with respect to contacting a cell with an agent (e.g., a compound disclosed herein) refers to any method suitable for placing an agent on, within, or adjacent to a target cell. For example, if the cell is in vitro, contacting the cell with an agent may include adding the agent to a culture medium containing the cell. For example, if the cell is in vivo, contacting the cell with an agent may include administering the agent to a subject.
[0242] As used herein, the term "administer" refers to the placement of an agent or composition as disclosed herein into a subject by a method or route that results in at least partial localization of the agent or composition at a desired site so that a desired effect occurs. Routes of administration suitable for the methods of the present invention include both local administration and systemic administration. In general, local administration results in more of the composition being delivered to a specific location compared to the tissue of the subject, while tissue administration results in delivery essentially to the tissue of the subject.
[0243] "Route of administration" refers to any route of administration, including, but not limited to, oral, topical, aerosol, intranasal, inhalation, anal, intraanal, perianal, transmucosal, transdermal, parenteral, enteral, or local, where "parenteral" can generally refer to routes of administration associated with injection, including: 1) intratumor, 2) intracranial, 3) intraventricular, 4) intrathecal, 5) epidural, 6) intradural, 7) intraorbital, 8) infusion, 9) intraarticular, 10) intracardiac, 11) intradermal, 12) intramuscular, 13) intraperitoneal, 14) intrapulmonary, 15) intraspinal, 16) intrasternal, 17) intrathecal, 18) intravascular, 19) intravenous, 20) intraarterial, 21) subarachnoid, 22) subcapsular, 23) subcutaneous, 24) transmucosal, or 25) transtracheal. If via parenteral route, the agent or composition may be in the form of a solution or suspension for infusion or injection, or may be a lyophilized powder. If via enteral route, the agent or composition may be in the form of a capsule, gel capsule, tablet, dragee, syrup, suspension, solution, powder, granule, emulsion, microsphere, nanoparticles consisting of proteinaceous or non-proteinaceous components, or nanosphere, or lipid vesicle, or polymer vesicle allowing controlled release. If via topical route, the agent or composition may be in the form of an aerosol, lotion, cream, gel, ointment, suspension, solution or emulsion. In one embodiment, the agent or composition may be provided in powder form and mixed with a liquid such as water to form a drink. According to the present invention, "administering" may be self-administered, for example, the subject may consume the composition disclosed herein.
[0244] Exemplary modes of administration include, but are not limited to, injection, infusion, infusion, inhalation, or ingestion. "Injection" includes, but is not limited to, 1) intravenous, 2) intramuscular, 3) intraarterial, 4) intrathecal, 5) intraventricular, 6) intraarticular, 7) intraorbital, 8) intracardiac, 9) intradermal, 10) intraperitoneal, 11) transtracheal, 12) subcutaneous, 13) subcuticular, 14) intraarticular, 15) subcapsular, 16) subarachnoid, 17) intraspinal, 18) intracerebrospinal, and 19) intrasternal injection and 20) infusion. In some embodiments of the various aspects described herein, the composition is administered by intravenous infusion or injection.
[0245] "Pharmaceutically acceptable salts", as used herein, are intended to include any compound described herein utilized in the form of its salt, particularly when the salt confers improved pharmacokinetic properties to the compound compared to the free form of the compound or a different salt form of the compound. Pharmaceutically acceptable salt forms can also confer desirable pharmacokinetic properties to a compound that it did not previously possess in the first place, and can even positively affect the pharmacodynamics of the compound with respect to its therapeutic activity in the body. An example of a pharmacokinetic property that can be favorably influenced is the manner in which the compound is transported across cell membranes, which can then directly and positively affect the absorption, distribution, biotransformation and excretion of the compound. The route of administration of a pharmaceutical composition is important, and various anatomical, physiological and pathological factors can have a significant effect on bioavailability, but the solubility of a compound usually depends on the properties of the particular salt form it utilizes. Those skilled in the art will appreciate that aqueous solutions of a compound provide the most rapid absorption of the compound into the body of a subject being treated, while lipid solutions and suspensions, as well as solid dosage forms, provide more rapid absorption of the compound.
[0246] Pharmaceutically acceptable salts include those of inorganic acids (e.g., sulfuric, sulfamic, phosphoric, nitric, and the like); and organic acids (e.g., acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanedisulfonic, oxalic, isothionic acids. See, e.g., Berge et al., "Pharmaceutical Salts," J. Pharm Sci. 66:1-19(1977), (1977), the contents of which are incorporated herein by reference in their entirety. Exemplary salts also include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, succinate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate salts, and the like. Suitable acids capable of forming salts with the compounds of the present disclosure include inorganic acids, such as hydrochloric acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and the like; and organic acids, such as 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, 2-naphthalenesulfonic acid, 3-phenylpropionic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, 4,4'-mephiylenebis(3-hydroxy-2-ene-1-carboxylic acid), acetic acid, anthranilic acid, phenylalanine ... These include benzenesulfonic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, cyclopentanepropionic acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, heptanoic acid, hydroxynaphthanoic acid, lactic acid, lauryl sulfuric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, muconic acid, naphthalenesulfonic acid, o-(4-hydroxybenzoyl)benzoic acid, oxalic acid, p-chlorobenzenesulfonic acid, propionic acid, p-toluenesulfonic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, tert-butylacetic acid, trifluoroacetic acid, and trimethylacetic acid. Suitable bases capable of forming salts with the compounds of the present disclosure include inorganic bases such as sodium hydroxide, ammonium hydroxide, sodium carbonate, calcium hydroxide, potassium hydroxide, and the like; and organic bases such as mono-, di-, and tri-alkyl and arylamines (e.g., triethylamine, diisopropylamine, methylamine, dimethylamine, N-methylglucamine, pyridine, picoline, dicyclohexylamine, N,N'-diphenylethylenediamine, and the like), and optionally substituted ethanolamines (e.g., ethanolamine, diethanolamine, triethanolamine, and the like).
[0247] The term "prodrug" as used herein refers to a compound that can be converted to the compounds described herein through some chemical or physiological process (e.g., enzymatic process and metabolic hydrolysis). Thus, the term "prodrug" also refers to a precursor of a biologically active compound that is pharma- ceutically acceptable. A prodrug may be inactive when administered to a subject as an ester, but is converted to an active compound in vivo, for example, by hydrolysis to a free carboxylic acid or free hydroxyl. Prodrug compounds often offer advantages of solubility, tissue compatibility, or delayed release in an organism. The term "prodrug" is also meant to include any covalently bonded carrier that releases an active compound in vivo when such a prodrug is administered to a subject. Prodrugs of active compounds can be prepared by modifying functional groups present in the active compound, as described herein, such that the modifications are cleaved to the parent active compound, either by routine manipulation or in vivo. Prodrugs include compounds in which a hydroxy, amino, or mercapto group is bonded to any group that is cleaved to form a free hydroxy, free amino, or free mercapto group, respectively, when the prodrug of the active compound is administered to a subject. For example, a compound containing a hydroxy group can be administered as an ester that is converted by hydrolysis in vivo to the hydroxy compound. Suitable esters that can be converted to hydroxy compounds in vivo include acetate, citrate, lactate, tartrate, malonate, oxalate, salicylate, propionate, succinate, fumarate, formate, benzoate, maleate, methylene-bis-b-hydroxynaphthalate, gentisate, isethionate, di-p-toluoyltartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate, quinic acid, esters of amino acids, and the like. Similarly, compounds containing an amine group may be administered as amides (e.g., acetamides, formamides, and benzamides), which are converted by hydrolysis in vivo to the amine compound. See, e.g., Harper, "Drug Latentiation" in Jucker, ed. Progress in Drug Research 4:221-294 (1962); Morozowich et al, "Application of Physical Organic Principles to Prodrug Design" in E. B. Roche ed. Design of Biopharmaceutical Properties through Prodrugs and Analogs, APHA Acad. Pharm. Sci. 40 (1977); Bioreversible Carriers in Drug in Drug Design, Theory and Application, E. B. Roche, ed., APHA Acad. Pharm. Sci. (1987); Design of Prodrugs, H. Bundgaard, Elsevier (1985); Wang et al. "Prodrug approaches to the improved delivery of peptide drug" in Curr. Pharm. Design. 5(4):265-287 (1999); Pauletti et al. (1997) Improvement in peptide bioavailability: Peptidomimetics and Prodrug Strategies, Adv. Drug. Delivery Rev. 27:235-256; Mizen et al. (1998) "The Use of Esters as Prodrugs for Oral Delivery of (3-Lactam antibiotics," Pharm. Biotech. ll,:345-365; Gaignault et al. (1996) "Designing Prodrugs and Bioprecursors I. Carrier Prodrugs," Pract. Med. Chem.671-696; Asgharnejad, "Improving Oral Drug Transport", in Transport Processes in Pharmaceutical Systems, G. L. Amidon, P. I. Lee and E. M. Topp, Eds., Marcell Dekker, p. 185-218 (2000); Balant et al., "Prodrugs for the improvement of drug absorption via different routes of administration", Eur. J. Drug Metab. Pharmacokinet., 15(2): 143-53 (1990); Balimane and Sinko, "Involvement of multiple transporters in the oral absorption of nucleoside analogues", Adv. Drug Delivery Rev., 39(1-3): 183-209 (1999); Browne, "Fosphenytoin (Cerebyx)", Clin. Neuropharmacol. 20(1): 1-12 (1997); Bundgaard, "Bioreversible derivatization of drugs- principle and applicability to improve the therapeutic effects of drugs", Arch. Pharm. Chemi 86(1): 1-39 (1979); Bundgaard H. "Improved drug delivery by the prodrug approach", Controlled Drug Delivery 17: 179-96 (1987); Bundgaard H. "Prodrugs as a means to improve the delivery of peptide drugs",Arfv. Drug Delivery Rev. 8(1): 1-38 (1992); Fleisher et al."Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Arfv. Drug Delivery Rev. 19(2): 115-130 (1996); Fleisher et al. "Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting", Methods Enzymol. 112 (Drug Enzyme Targeting, Pt. A): 360-81, (1985); Farquhar D, et al., "Biologically Reversible Phosphate-Protective Groups", Pharm. Sci., 72(3): 324-325 (1983); Freeman S, et al., "Bioreversible Protection for the Phospho Group: Chemical Stability and Bioactivation of Di(4-acetoxy-benzyl) Methylphosphonate with Carboxyesterase," Chem. Soc., Chem. Commun., 875-877 (1991); Friis and Bundgaard, "Prodrugs of phosphates and phosphonates: Novel lipophilic alphaacyloxyalkyl ester derivatives of phosphate- or phosphonate containing drugs masking the negative charges of these groups", Eur. J. Pharm. Sci. 4: 49-59 (1996); Gangwar et al., "Pro-drug, molecular structure and percutaneous delivery", Des. Biopharm. Prop.Prodrugs Analogs, [Symp.] Meeting Date 1976, 409-21. (1977); Nathwani and Wood, "Penicillins: a current review of their clinical pharmacology and therapeutic use", Drugs 45(6): 866-94 (1993); Sinhababu and Thakker, "Prodrugs of anticancer agents", Adv. Drug Delivery Rev. 19(2): 241-273 (1996); Stella et al., "Prodrugs. Do they have advantages in clinical practice?", Drugs 29(5): 455-73 (1985); Tan et al. "Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics", Adv. Drug Delivery Rev. 39(1-3): 117-151 (1999); Taylor, "Improved passive oral drug delivery via prodrugs", Adv. Drug Delivery Rev., 19(2): 131-148 (1996); Valentino and Borchardt, "Prodrug strategies to enhance the intestinal absorption of peptides", Drug Discovery Today 2(4): 148-155 (1997); Wiebe and Knaus, "Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection", Adv.Drug Delivery Rev.: 39(1-3):63-80 (1999); Waller et al., "Prodrugs", Br. J. Clin. Pharmac. 28: 497-507 (1989), content of all of which are herein incorporated by reference in its entirety.
[0248] How to Treat Cancer
[0249] In various embodiments, the present invention provides a method for treating, inhibiting, reducing the severity, preventing metastasis and / or delaying the progression of cancer in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of an agonist of GITR. In one embodiment, the agonist is a peptide having a sequence as set forth in SEQ ID NO:1. In another embodiment, the agonist is a peptide having a sequence as set forth in SEQ ID NO:2. In further embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising a peptide having a sequence as set forth in SEQ ID NO:1 and SEQ ID NO:2. In some embodiments, the GITR agonist is administered in combination with an existing treatment for cancer. In some embodiments, the GITR agonist and the existing treatment are administered simultaneously or sequentially. In one embodiment, the GITR agonist is administered prior to administration of an existing treatment for cancer. In some embodiments, the GITR agonist is administered after administration of an existing treatment for cancer. In further embodiments, the GITR agonist is administered simultaneously with an existing treatment for cancer.
[0250] A method for reducing regulatory T cells (Treg cells) (T-reg cells) in a tumor microenvironment is also provided by the present invention. The method comprises administering to a subject a therapeutically effective amount of an agonist of GITR. In one embodiment, the agonist is a peptide having a sequence as set forth in SEQ ID NO:1. In another embodiment, the agonist is a peptide having a sequence as set forth in SEQ ID NO:2. In a further embodiment, the method comprises administering to a subject a therapeutically effective amount of a composition comprising a peptide having a sequence as set forth in SEQ ID NO:1 and SEQ ID NO:2.
[0251] In some embodiments, the GITR agonist for use in treating cancer is a compound having the structure shown in Formula I.
[0252] In another embodiment, the present invention relates to administering to a patient suffering from cancer a sample of cells enriched for T-effector cells, where enrichment is achieved by contacting the T-effector cells with a GITR agonist as described in formula I, with or without T-reg cells. The T-effector cells or T-reg cells can be autologous or allogeneic to the patient. In particular, the GITR agonist can be RMGL171102, aka 11702 compound.
[0253] In exemplary embodiments, the cancer is B-cell lymphoma (Hodgkin's lymphoma and / or non-Hodgkin's lymphoma), brain cancer, breast cancer, colon cancer, lung cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, urinary tract cancer, thyroid cancer, renal cancer, carcinoma, melanoma, head and neck cancer, brain cancer, and prostate cancer, androgen-dependent prostate cancer and androgen-independent prostate cancer, and in particular melanoma or lymphoma.
[0254] Methods for Treating Autoimmune Diseases
[0255] Also provided herein is a method for treating, inhibiting, or reducing the severity of an autoimmune disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a GITR antagonist.
[0256] In some embodiments, a GITR antagonist for use in treating an inflammatory disease, such as an autoimmune disease, is a compound having the structure shown in Formula II.
[0257] In another embodiment, the present invention relates to administering to a patient suffering from an inflammatory disease, particularly an autoimmune disease, a sample of cells enriched in T-reg cells or modified in T-eff cells, where enrichment is achieved by contacting T-effector cells (T-eff cells) with a GITR antagonist as shown in formula II, with or without T-reg cells. The T-effector cells or T-reg cells can be autologous or allogeneic to the patient. In particular, the GITR antagonist can be RMGL171104, aka 11704 compound.
[0258] In some embodiments, the GITR antagonist is administered in combination with an existing treatment for an autoimmune disease. In some embodiments, the GITR antagonist and the existing treatment are co-administered or administered simultaneously. In one embodiment, the GITR antagonist is administered before the administration of an existing treatment for an autoimmune disease. In some embodiments, the GITR antagonist is administered after the administration of an existing treatment for an autoimmune disease. In a further embodiment, the GITR antagonist is administered simultaneously with an existing treatment for an inflammatory disease or an autoimmune disease.
[0259] In exemplary embodiments, the inflammatory disease is acute or chronic pancreatitis and the autoimmune disease is rheumatoid arthritis, osteoarthritis, asthma, dermatitis, psoriasis, cystic fibrosis, late post-transplant and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, Hashimoto's thyroiditis, polymyositis, scleroderma, Addison's disease, vitiligo, pernicious anemia, glomerulonephritis and pulmonary fibrosis, inflammatory bowel disease, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, restenosis after angioplasty, chronic obstructive pulmonary disease (COPD), Graves' disease, gastrointestinal allergies, conjunctivitis, arteriosclerosis, atherosclerosis, coronary artery disease, angina, metastasis, small artery disease, graft versus host disease, mitochondrial-related syndromes, particularly those in arthritis or organ transplantation.
[0260] Combination therapy
[0261] In exemplary embodiments, existing treatments for cancer for use in combination with the GITR agonists described herein include, but are not limited to, chemotherapy, radiation therapy, hormonal therapy, surgery, immunotherapy, or a combination thereof.
[0262] In some embodiments, the chemotherapeutic agent may be selected from any one or more of cytotoxic antibiotics, antimetabolites, mitotic inhibitors, alkylating agents, arsenic compounds, DNA topoisomerase inhibitors, taxanes, nucleoside analogs, plant alkaloids, and toxins; and synthetic derivatives thereof. Exemplary compounds include alkylating agents: treosulfan, and trofosfamide; plant alkaloids: vinblastine, paclitaxel, docetaxol; DNA topoisomerase inhibitors: doxorubicin, epirubicin, etoposide, camptothecin, topotecan, irinotecan, teniposide, crisnatol, and mitomycin; antifolates: methotrexate, mycophenolic acid, and hydroxyurea; pyrimidine analogs: 5-fluorouracil, doxifluridine, and cytosine arabinoside; purine analogs: mercaptopurine and thioguanine; DNA antimetabolites: 2'-deoxy-5-fluorouridine, aphidicolin glycinate, and pyrazoloimidazole; and antimitotic agents: halichondrin, colchicine, and rhizoxin. Compositions containing one or more chemotherapeutic agents (e.g., FLAG, CHOP) may also be used. FLAG includes fludarabine, cytosine arabinoside (Ara-C) and G-CSF. CHOP includes cyclophosphamide, vincristine, doxorubicin, and prednisone. In another embodiment, a PARP (e.g., PARP-1 and / or PARP-2) inhibitor is used, such inhibitors being well known in the art (e.g., Olaparib, ABT-888, BSI-201, BGP-15 (N-Gene Research Laboratories, Inc.); INO-1001 (Inotek Pharmaceuticals Inc.); PJ34 (Soriano et al., 2001; Pacher et al., 2002b); 3-aminobenzamide (Trevigen); 4-amino-1,8-naphthalimide; (Trevigen); 6(5H)-phenanthridinone (Trevigen); benzamide (U.S. Reissue Patent No. 36,397); and NU1025 (Bowman et al.).
[0263] In various embodiments, radiation therapy can be ionizing radiation.Radiation therapy can also be gamma rays, X-rays, or proton beams.Examples of radiation therapy include, but are not limited to, external beam radiation therapy, interstitial implantation of radioisotopes (I-125, palladium, iridium), radioisotopes such as strontium-89, chest radiation therapy, intraperitoneal P-32 radiation therapy, and / or total abdominal and pelvic radiation therapy. For a general overview of radiation therapy, see Hellman, Chapter 16: Principles of Cancer Management: Radiation Therapy, 6th edition, 2001, DeVitaet al., eds. JB Lippencott Company, Philadelphia. Radiation therapy can be administered as external beam radiation or teletherapy, directed from a distant radiation source. Radiation therapy can also be administered as internal therapy or brachytherapy, in which a radioactive source is placed inside the body in close proximity to the cancer cells or tumor mass. Also encompassed is the use of photodynamic therapy, which includes the administration of photosensitizers such as hematoporphyrin and its derivatives, vertoporphin (BPD-MA), phthalocyanines, photosensitizer Pc4, demethoxy-hypocrelin A; and 2BA-2-DMHA.
[0264] In various embodiments, immunotherapy may include, for example, the use of cancer vaccines and / or sensitized antigen-presenting cells. In some embodiments, the treatment includes targeting cells in the tumor microenvironment or targeting immune cells. Immunotherapy may include passive immunity for short-term protection of the host, achieved by administration of preformed antibodies against cancer or disease antigens (e.g., administration of monoclonal antibodies to tumor antigens, optionally linked to chemotherapeutic agents or toxins). Immunotherapy may also focus on using cytotoxic lymphocyte-recognized epitopes of cancer cell lines.
[0265] In various embodiments, hormone therapy may include, for example, hormone agonists, hormone antagonists, hormone antagonists (e.g., flutamide, bicalutamide, tamoxifen, raloxifene, leuprolide acetate (LUPRON), LH-RH antagonists), inhibitors of hormone biosynthesis and processing, as well as steroids (e.g., dexamethasone, retinoids, deltoids, betamethasone, cortisol, cortisone, prednisone, dehydrotestosterone, glucocorticoids, mineralocorticoids, estrogens, testosterone, progestins), vitamin A derivatives (e.g., all-trans retinoic acid (ATRA)); vitamin D3 analogs; antigestagens (e.g., mifepristone, onapristone), or antiandrogens (e.g., cyproterenoacetate).
[0266] In some embodiments, existing treatments for autoimmune diseases include, but are not limited to, physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-inflammatory drugs (DMARDs), anti-cytokine therapy, inhibition of intracellular signaling pathways, costimulation inhibition, biological inhibitors of T cell function, B cell anergy and depletion, regulatory T cells, stem cell transplantation and / or hematopoietic stem cell transplantation.
[0267] In certain instances, one or more GITR antagonists or GITR antagonists described herein can be used in combination with other current or future drug therapies because the effect of one or more GITR antagonists or GITR antagonists described herein alone is not optimal by itself and / or is synergistic or highly effective with a treatment acting on a separate pathway that functionally interacts with one or more GITR antagonists or GITR antagonists described herein. In certain instances, the co-administration of one or more GITR agonists or GITR antagonists as described herein with an additional drug therapy reduces the dosage of the additional drug therapy to be below the amount that would achieve a therapeutic effect if it were used as a monotherapy.
[0268] In some embodiments, one or more GITR agonists described herein may be combined (sequentially or simultaneously) with a checkpoint inhibitor. In various embodiments, examples of immune checkpoint inhibitors for use with the GITR agonists described herein include anti-PD-1 antibodies, such as Lambrolizumab (MK-3475), Nivolumab (CT-936558), and Pidiligumab (CT-011), anti-PD-L1 antibodies, such as MPDL3280A (RG7446), MEDI4736, and BMS-936559, anti-PD-L2 antibodies, B7-DC-Fc fusion proteins, such as AMP-224, anti-CTLA-4 antibodies, such as tremelimumab (CP-675,206) and ipilimumabu (MDX-010), antibodies against the B7 / CD28 receptor superfamily, anti-indoleamine (2,3)-dioxygenase (IDO) antibodies, anti-IDO1 antibodies, anti-IDO2 antibodies, tryptophan, tryptophan mimetics, 1-methyltryptophan (1-MT), indoximod (D-1-MT), L-1-methyltryptophan (L-1-MT), hydroxyamidine inhibitors such as TX-2274 and INCB024360, anti-TIM-3 antibodies, anti-LAG-3 antibodies such as BMS-986016, recombinant soluble LAG-3Ig fusion proteins acting on MHC class II-driven dendritic cell activation such as IMP321, anti-KIR2DL1 / 2 / 3 antibodies or anti-KIR antibodies such as lirilumab (IPH2102), anti-phosphatidylserine (anti-PS) antibodies such as urelumab (BMS-663513) and bavituximab, anti-idiotypic mouse monoclonal antibodies against N-glycolyl-GM3 ganglioside (previously known as 1E10) such as racotumomab, and IgGCD134. These include, but are not limited to, anti-OX40R antibodies such as mAbs, anti-B7-H3 antibodies such as MGA271, and small interfering (si)RNA-based cancer vaccines designed to treat cancer by silencing immune checkpoint genes. Further information can be found in Creelan BC (Update on immune checkpoint inhibitors in lung cancer, Cancer Control. 2014 Jan; 21(1):80-9) and Jane de Lartigue (Another Immune Checkpoint Emerges as Anticancer Target, Published by online by onclive.com, Tuesday, September 24, 2013). In some embodiments, the immune checkpoint inhibitor is selected from the group consisting of an antibody against PD-1, an antibody against PD-L1, an antibody against PD-L2, an antibody against CTLA-4, an antibody against KIR, an antibody against IDO1, an antibody against IDO2, an antibody against TIM-3, an antibody against LAG-3, an antibody against OX40R, and an antibody against PS, or a combination thereof.
[0269] In various embodiments, the GITR antagonists described herein can be used in combination with existing therapies that increase the levels of Treg cells. In exemplary embodiments, the GITR antagonists can be used in combination (sequentially or simultaneously) with TNF inhibitors, including monoclonal antibodies such as infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia), and golimumab (Simponi), or with circulating receptor fusion proteins such as etanercept (Enbrel).
[0270] kit In various embodiments, the present invention provides kits for treating cancer and inflammatory diseases (e.g., autoimmune diseases) that include one or more GITR agonists (for treating cancer) or GITR antagonists (for treating autoimmune diseases) and instructions for use.
[0271] The exact nature of the components configured in the kit of the present invention will depend on its intended purpose. In one embodiment, the kit is configured specifically for human subjects. In a further embodiment, the kit is configured for veterinary applications, treating subjects such as, but not limited to, farm animals, livestock, and laboratory animals.
[0272] Instructions for use may be included in the kit. "Instructions for use" typically include a tangible manifestation describing techniques to be used in using the components of the kit to produce a desired result, e.g., to treat cancer or an autoimmune disease. Optionally, the kit also includes other useful components, such as measuring tools, diluents, buffers, pharmaceutical compositions, pharma- ceutically acceptable carriers, syringes, or other useful paraphernalia (easily recognized by those of skill in the art).
[0273] The materials or components assembled in the kit can be stored and provided to the practitioner in any convenient and appropriate manner that maintains their operability and usefulness. For example, the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room temperature, refrigerated temperature, or frozen temperature. The components are typically included in suitable packaging materials. The phrase "packaging material" as used herein refers to one or more physical structures used to contain the contents of the kit, such as the compositions of the present invention, and the packaging material is preferably constructed by well-known methods to provide a sterile, contaminant-free environment. The term "package" as used herein refers to a suitable solid matrix or material, such as glass, plastic, paper, foil, etc., capable of holding individual kit components. The packaging material generally has an exterior label indicating the contents and / or purpose of the kit and / or its components.
[0274] The various methods and techniques described above provide many ways to implement the present application. Of course, it should be understood that not all objects or advantages described may be achieved in accordance with any particular embodiment described herein. Thus, for example, one skilled in the art will recognize that a method can be implemented in a manner that achieves or optimizes one or a group of advantages as taught herein, without necessarily achieving other objects or advantages as taught or suggested herein. Various alternatives are mentioned herein. It should be understood that some preferred embodiments include, in particular, one, another, or several features, other embodiments exclude, in particular, one, another, or several features, while other embodiments reduce certain features by including one, another, or several advantageous features.
[0275] Moreover, one skilled in the art will recognize the applicability of various features from different embodiments. Similarly, the various elements, features, and steps described above, as well as other known equivalents for each such element, feature, or step, may be used in various combinations by one skilled in the art to carry out methods in accordance with the principles described herein. Among the various elements, features, and steps, some are specifically included and others are specifically excluded in various embodiments.
[0276] Although the present application has been disclosed in the context of particular embodiments and examples, it will be understood by those skilled in the art that the embodiments of the present application extend beyond the specifically disclosed embodiments to other alternative embodiments and / or uses and modifications thereof and equivalents.
[0277] Preferred embodiments of the application are described herein, including the best mode known to the inventors for carrying out the application. Variations of these preferred embodiments will become apparent to those of skill in the art upon reading the foregoing description. Such variations can be employed by those of skill in the art as appropriate, and it is contemplated that the application can be carried out in ways other than as specifically described herein. Accordingly, many embodiments of the application include all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations of such elements is encompassed by the application unless otherwise indicated herein or clearly contradicted by context.
[0278] All patents, patent applications, patent application publications, and other materials such as literature, books, specifications, publications, documents, things, and / or the like are referenced herein and are incorporated by reference in their entirety for all purposes, except for all application file histories (wrappers) relating to the same or something similar that may contradict or conflict with the subject matter of the invention, or have a limiting effect on the broadest invention of the present claims or the invention of any later related claims. By way of example, in the event of a conflict or inconsistency between the explanation, definition, and / or use of a term associated with any of the incorporated materials and that term associated with this document, the explanation, definition, and / or use of the term in this document shall control.
[0279] It should be understood that the embodiments of the present application disclosed herein are illustrative of the principles of the embodiments of the present application. Other modifications that may be used may be within the scope of the present application. Thus, by way of example, and not of limitation, alternative configurations of the embodiments of the present application may be utilized in accordance with the teachings of the present specification. Thus, the embodiments of the present application are not limited to those precisely as shown and described.
[0280] Various embodiments of the present invention have been described above in the detailed description. Although these descriptions directly describe the above embodiments, it should be understood that those skilled in the art may consider modifications and / or variations to the specific embodiments shown and described herein. Any such modifications or variations that fall within the scope of this description are intended to be included therein as well. Unless otherwise stated, it is the inventor's intention that the words and phrases in the specification and claims be given their ordinary and accustomed meaning to those of ordinary skill in the applicable technical field.
[0281] The foregoing description of various embodiments of the present invention known to the applicant at the time of filing this application has been presented for purposes of illustration and description. The description is not intended to be exhaustive or to limit the invention to the precise form disclosed, as many modifications and variations are possible in light of the above teachings. The described embodiments serve to illustrate the principles of the present invention and its practical application, and to enable others skilled in the art to utilize the present invention in various embodiments and various modifications suited to the particular use intended. Therefore, it is not intended that the invention be limited to the specific embodiments disclosed for carrying out the invention.
[0282] Working Example
[0283] The following examples are provided to better illustrate the claimed invention and should not be construed as limiting the scope of the claimed invention. To the extent that specific materials are mentioned, they are merely for illustrative purposes and are not intended to limit the invention. Those skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the claimed invention.
[0284] Example 1 GITR agonists reduce Treg populations in human blood
[0285] CD4 + CD25 - CFES +The population (T effector cells) was measured in a T cell suppression assay when mixed with Treg cells in the setting of T cell activation by antigen presenting cells. Control results show that T regulatory cells can inhibit 15% of T cell proliferation. GITR agonists lead to a dose-dependent expansion of T effector cells and their activity, and are more effective in the presence of Tregs, suggesting an effect on T effectors and Tregs. The GITRL antagonist 11704 caused a dose-dependent regression of T effector cells and its activity was more effective in the presence of Tregs, suggesting an effect on T effectors and Tregs.
[0286] Example 2 T cell suppression assay (in vitro human cells)
[0287] Example 2.1 - Methods
[0288] PBMCs were isolated from WBC cones collected from healthy platelet donors (Ficoll, GE Healthcare). Cells were washed and passed through a 40 μm cell strainer before staining with T cell surface antibodies. Cells were then placed on a cell sorter (BD FACSARIA III). Specific cell populations were identified as CD4 + CD25 - T effector cells, CD4 + CD25 + CD45RA + CD127 - T regulatory cells and CD3 - T-reg cells (which act as antigen-presenting cells, APCs) were prepared. T effector cells were labeled with CellTrace CFSE (Invitrogen) and washed extensively before cell counting. Effector cells and T-regs were then mixed together in a 1:1 ratio in culture medium (RPMI 1640, 10% FBS, Pen-Strep, and 1% NEAA) enriched with anti-CD3 (3 μg / ml) and anti-CD28 (2 μg / ml) antibodies. APCs were incubated at 37°C, 5% CO 2The cells were treated with mitomycin (50 μg / ml) for 30 min in an incubator, and then added to the culture mix (APC:T-eff 2:1) as a proliferation co-stimulator. The cell mixture was incubated at 37 °C, 5% CO 2 After incubation for 6 days, the cells were re-stained with T cell surface markers (CD4, CD25) and sent for FACS analysis (Figures 1A-1B, 4 and 5).
[0289] Molecules 11702 and 11704 were added to the treatment groups in a concentration gradient of 5 μM, 25 μM and 50 μM, respectively.
[0290] Example 2.2 result
[0291] FACS results show that CD4 + CD25 - CFES + The image focuses on a population (T effector cells). CFSE fluorescence shows distinct peaks, each peak representing one generation of T lymphocyte proliferation. As the T cells proliferate and replicate, the CFSE peaks extend successively to the left and become less fluorescent (towards the negative range). The further the cell population moves to the left, the stronger the proliferation.
[0292] Control results show that T regulatory cells are able to inhibit 15% of T cell proliferation.
[0293] Example 3 Effect of RMGL171102 on T effector cells
[0294] Addition of RMGL171102 (Chembridge, Inc. San Diego, ID no. 5483007) to T effectors (without T-regs) showed that the molecule alone was highly effective in accelerating T cell proliferation at all three concentrations, with the most effective dose being around 25 μM (increasing the proliferating population by 61.7% compared to baseline, 47.4% at 5 μM, and 52% at 50 μM) (Figures 2A-2C, 4 and 5).
[0295] Within the T-reg group (RMGL171102+T-reg), the results show a very strong stimulation of T cell proliferation compared to the T control group (no molecule): a 34.4% increase at 5 μM, 96.7% at 25 μM and 107.1% at 50 μM (Figures 2D-2F, 4 and 5).
[0296] Example 4 Effect of RMGL171104 on T cells
[0297] Addition of RMGL171104 alone (Chembridge, Inc. San Diego, ID number 5470140) to T effectors (without T-regs) shows inhibition of T cell proliferation (39.1% reduction) at a concentration of 50 μM, but has no significant effect on T effector cells at 5 μM and 25 μM (Figures 3A-3C, 4 and 5).
[0298] Once T-regs were engaged, the molecule began to show more effective inhibition of proliferating T cells at 25 μM (33.9% reduction) and was most effective at 50 μM (55.9% reduction in proliferation compared to baseline) (Figures 3D-3F, 4 and 5).
[0299] Example 5 GITR agonist 11702 inhibits melanoma growth through Teff proliferation and Treg inhibition in tumors
[0300] After implantation of B16 melanoma, C57 BL mice were treated with 11702 GITR agonist or DMSO control. Figure 6 shows that (A) animals survived longer after intraperitoneal 30 mg / kg treatment of GITR agonist twice weekly (p=0.0333, log rank). (B) Tumor volume was inhibited in 11702 treated animals (p<0.05, Anova). (C) FAC analysis of tumor-infiltrating lymphocytes showed that activated CD4 + Increased presence of effector memory cytotoxic CD8 cells +Both groups showed increased PD-1 expression, suggesting that IFNγ induces upregulation of PD-1, leading to potential synergy between this agent and PD-1 checkpoint blockade.
[0301] While particular embodiments of the present invention have been shown and described, it will be apparent to those skilled in the art that, based on the teachings herein, changes and modifications can be made without departing from this invention and its broader aspects, and therefore, the appended claims are intended to encompass within their scope all such changes and modifications that are within the true spirit and scope of this invention.
Claims
1. A method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a GITR / GITRL agonist.
2. The GITR / GITRL agonist is a compound of formula I: 【Chemistry 1】 、 or a pharma- ceutically acceptable salt, ester or prodrug thereof; Where: R1 is hydrogen or an optionally substituted substituent; R2 is hydrogen or an optionally substituted substituent; R3 is hydrogen or an optionally substituted substituent; R4 is hydrogen or an optionally substituted substituent; R5 is hydrogen or an optionally substituted substituent; R6 is hydrogen or an optionally substituted substituent; R7 is hydrogen or an optionally substituted substituent, and R8 is hydrogen or an optionally substituted substituent; Here. wherein any two or more of R1, R2, R3, R4, R5, R6, R7, or R8 may be joined together to form one or more rings.
3. The method according to claim 2, wherein the GITR / GITRL agonist compound is represented by the following formula: 【Chemistry 2】
4. 2. The method of claim 1, wherein the GITR / GITRL agonist is represented by a peptide having the sequence of SEQ ID NO: 1 or 2, or a variant, derivative or functional equivalent thereof.
5. 10. The method of claim 1, further comprising administering to the subject an existing treatment for cancer, either simultaneously or sequentially.
6. 2. The method of claim 1, wherein the cancer is T-cell / B-cell lymphoma (Hodgkin's lymphoma and / or non-Hodgkin's lymphoma), brain cancer, breast cancer, colon cancer, lung cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, ureter cancer, thyroid cancer, kidney cancer, carcinoma, skin cancer, head and neck cancer, brain cancer, and prostate cancer, androgen-dependent prostate cancer and androgen-independent prostate cancer.
7. 7. The method of claim 6, wherein the skin cancer is melanoma.
8. 1. A method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a sample of enriched or expanded T-eff cells, wherein the T-eff cells are contacted with a GITR / GITRL agonist in the presence or absence of T-reg cells, thereby enriching or expanding the T-eff cells.
9. The method of claim 8, wherein the T-eff or T-reg cells are autologous to the subject.
10. The method of claim 8, wherein the T-eff cells or T-reg cells are allogeneic to the subject.
11. GITR / GITRL agonists are 【Chemistry 3】 Compounds of or a pharma- ceutically acceptable salt, ester or prodrug thereof; Where: R1 is hydrogen or an optionally substituted substituent; R2 is hydrogen or an optionally substituted substituent; R3 is hydrogen or an optionally substituted substituent; R4 is hydrogen or an optionally substituted substituent; R5 is hydrogen or an optionally substituted substituent; R6 is hydrogen or an optionally substituted substituent; R7 is hydrogen or an optionally substituted substituent, and R8 is hydrogen or an optionally substituted substituent; wherein any two or more of R1, R2, R3, R4, R5, R6, R7, or R8 may be bonded together to form one or more rings.
12. The method according to claim 11, wherein the compound of formula I is 【Chemistry 4】
13. A method for enriching or expanding T-eff cells, comprising contacting T-eff cells, in the presence or absence of T-reg cells, with a GITR / GITRL agonist.
14. The method of claim 13, wherein T-reg cells are present.
15. GITR / GITRL agonists are 【Chemistry 5】 Compounds of or a pharma- ceutically acceptable salt, ester or prodrug thereof; Where: R1 is hydrogen or an optionally substituted substituent; R2 is hydrogen or an optionally substituted substituent; R3 is hydrogen or an optionally substituted substituent; R4 is hydrogen or an optionally substituted substituent; R5 is hydrogen or an optionally substituted substituent; R6 is hydrogen or an optionally substituted substituent; R7 is hydrogen or an optionally substituted substituent, and R8 is hydrogen or an optionally substituted substituent; wherein any two or more of R1, R2, R3, R4, R5, R6, R7, or R8 may be bonded together to form one or more rings. The method of claim 13.
16. The method of claim 11, wherein the compound of formula I is 【Chemistry 6】
17. The method of claim 14, wherein the T-eff cells and T-reg cells are present at a starting ratio of about 1:
1.
18. A method for treating an inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a GITR / GITRL antagonist.
19. GITR / GITRL antagonists are of formula II 【Chemistry 7】 Compounds of or a pharma- ceutically acceptable salt, ester or prodrug thereof; Where: R9 is hydrogen or an optionally substituted substituent; R10 is hydrogen or an optionally substituted substituent; R11 is hydrogen or an optionally substituted substituent; R12 is hydrogen or an optionally substituted substituent; R13 is hydrogen or an optionally substituted substituent; R14 is hydrogen or an optionally substituted substituent; R15 is hydrogen or an optionally substituted substituent; and R16 is hydrogen or an optionally substituted substituent; Where: any two or more of R9, R10, R11, R12, R13, R14, R15, or R16 may be bonded together to form one or more rings; method.
20. 20. The method of claim 19, wherein the GITR / GITRL antagonist compound is 【Chemistry 8】 。
21. 19. The method of claim 18, wherein the inflammatory disease is an autoimmune disease.
22. 20. The method of claim 18, further comprising administering to the subject, either simultaneously or sequentially, an existing treatment for the inflammatory disease.
23. 22. The method of claim 21, wherein the autoimmune disease is rheumatoid arthritis, osteoarthritis, asthma, dermatitis, psoriasis, cystic fibrosis, late transplant and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, Hashimoto's thyroiditis, polymyositis, scleroderma, Addison's disease, vitiligo, pernicious anemia, glomerulonephritis and pulmonary fibrosis, inflammatory bowel disease, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), Graves' disease, gastrointestinal allergy, conjunctivitis, atherosclerosis, coronary artery disease, angina, cancer metastasis, small artery disease, graft-versus-host disease, or mitochondrial-related syndrome.
24. 24. The method of claim 23, wherein the autoimmune disease is inflammatory bowel disease.
25. A method for treating an inflammatory disease in a subject in need thereof, comprising administering a therapeutically effective amount of a GITR / GITRL antagonist in vivo or engineered T cells that have been enriched or expanded in T-regs in vivo or ex vivo, wherein the engineered T cells enrich or expand T-reg cells and wherein T-eff cells are modified by contacting the T-eff cells with a GITR / GITRL antagonist in the presence or absence of T-reg cells.
26. The method of claim 25, wherein the T-eff or T-reg cells are autologous to the subject.
27. The method of claim 25, wherein the T-eff or T-reg cells are allogeneic to the subject.
28. GITR / GITRL antagonists are of formula II 【Chemistry 9】 Compounds of or a pharma- ceutically acceptable salt, ester or prodrug thereof, Where: R9 is hydrogen or an optionally substituted substituent; R10 is hydrogen or an optionally substituted substituent; R11 is hydrogen or an optionally substituted substituent; R12 is hydrogen or an optionally substituted substituent; R13 is hydrogen or an optionally substituted substituent; R14 is hydrogen or an optionally substituted substituent; R15 is hydrogen or an optionally substituted substituent; and R16 is hydrogen or an optionally substituted substituent; Where: any two or more of R9, R10, R11, R12, R13, R14, R15, or R16 may be bonded together to form one or more rings; method.
29. 29. The method of claim 28, wherein the GITR / GITRL antagonist compound is 【Chemistry 10】
30. A method for enriching or expanding T-reg cells, comprising contacting T cells, with or without the presence of T-eff cells, with a GITR / GITRL antagonist.
31. The method of claim 30, wherein T-reg cells are present in the early stage.
32. 32. The method of claim 31 , wherein the T-eff cells and T-reg cells are present at a starting ratio of about 1:
1.
33. GITR / GITRL antagonists are of formula II 【Chemistry 11】 Compounds of or a pharma- ceutically acceptable salt, ester or prodrug thereof; Where: R9 is hydrogen or an optionally substituted substituent; R10 is hydrogen or an optionally substituted substituent; R11 is hydrogen or an optionally substituted substituent; R12 is hydrogen or an optionally substituted substituent; R13 is hydrogen or an optionally substituted substituent; R14 is hydrogen or an optionally substituted substituent; R15 is hydrogen or an optionally substituted substituent; and R16 is hydrogen or an optionally substituted substituent; Where: any two or more of R9, R10, R11, R12, R13, R14, R15, or R16 may be bonded together to form one or more rings; method.
34. 34. The method of claim 33, wherein the GITR / GITRL antagonist compound is 【Chemistry 12】
